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INTRODUCTION 
In early times, poison was discovered by tribes as a hunting tool to 
catch their prey. Later poisons grew more advanced and were used for 
various purposes, usually weapons, anti-venoms and medicines. Recently it is 
used in the field of toxicology and for other technologies. 
Though poison was used for constructive purposes, our mankind 
realized the danger of poison, when people misused it as a means for 
committing suicide. Even a small portion of consumption leads to loss of 
human life.  
Rodenticides, which are easily available in households contribute a lot 
in consumption. It is highly dangerous and people are mostly not aware of its 
toxicity effect which result in high death rate. 
This study shows the clinical and biochemical values of patients who 
consumed the Rodenticides. Usually Rodenticides are available in different 
forms such as past, powder, baits etc. 
It is available in markets both as a local product as well as in branded 
product. Normally branded products has the chemical names and content 
printed on it whereas the local product does not show any chemical names on 
it. 
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Our study mainly conclude that the Rodenticides in paste form are 
more toxic. But the powdered and bait Rrodenticides also produces 
significant manifestation both clinically and bio chemically. 
 
  
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
1) To study the clinical profile of patients with different Rodenticide 
compounds. 
2) To study the biochemical profile of patients admitted in toxicology 
ward with Rodenticide  poisoning. 
 
 
 
 
 
 
 
 
 
 
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
Rotenticides, actually meant rat poison is manufactured mainly to kill 
rodents.  
It is easily available in India due to its low cost and affordability.  
Some Rodenticides are toxic, some are less toxic. It is available in 
many forms, each one of which carries significant role in killing the rodents 
and making clinical and biochemical variations. 
After ingestion it is not only toxic to rodents but it is also toxic to 
humans and animals. Normally it is made in baits to attract animals. Baits are 
commonly used in the area containing ground meats, fruits and vegetables 
and also in the agricultural areas.1 
Rodenticides are heterogeneous group of compounds that create high 
toxicities to human and animals and it is considered as a high toxic substance 
which are available in homes. In before the mid of 20th century metals like 
are arsenium and thallium were mostly used agent to make these 
Rodenticides. 
They are available in different forms such as powder, bait and paste. 
Each one of it carries different action based on the content and percentage of 
the ingredients. They are available in local form and branded forms. 
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AVAILABLE OF RODENTICIDE IN SHOPS IN LOCAL BRANDS 
Classification of Rodenticides. 
Rodenticides are classified based on its chemical group. Some 
Rodenticides acts as anticoagulant (warfar in) which stops the normal clotting 
mechanism. Recently rodents have now become resistant to warfarin baits. 
The new development of super warfarin have increased the risk to humans.2,3 
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T6Table 1. ACUTE TOXICITY CLASSIFICATION – RODENTICIDES 
 
Oral Inhalation Dermal 
Primary 
Eye 
Irritation 
Primary 
Skin 
Irritation 
Warfarin3,6 
Moderate 
- High 
toxicity 
Not 
significant 
Not 
significant No data No data 
Chlorphacinone4 High toxicity 
High 
toxicity 
High 
toxicity 
Non-
irritating 
Non-
irritating 
Diphacinone4 High toxicity 
High 
toxicity 
High 
toxicity 
Moderate 
irritation 
Slight 
irritation 
Bromadiolone4 High toxicity 
High 
toxicity 
High 
toxicity 
Low 
irritation 
Minimally 
irritating 
Difethialone3 High toxicity 
High 
toxicity 
High 
toxicity 
Mild 
irritant 
Non-
irritating 
Brodifacoum4 High toxicity 
High 
toxicity 
High 
toxicity 
Minor 
irritation 
Mild 
irritant 
Bromethalin4 High toxicity 
High 
toxicity 
Moderate 
toxicity 
Slight 
irritation 
Non-
irritating 
Cholecalciferol3 High toxicity 
Very low 
toxicity 
Low 
toxicity No data No data 
Zinc phosphide5 High toxicity 
High 
toxicity 
Low 
toxicity 
Slight 
irritation 
Non-
irritating 
Strychnine7 High toxicity 
High 
toxicity 
Low 
toxicity 
Highly 
irritating 
Non-
irritating 
Classification categories were modeled after the U.S. Environmental Protection Agency, 
Office of Pesticide Programs, Label Review Manual, Chapter 7: Precautionary Labeling. 
http://www.epa.gov/oppfead1/labeling/lrm/chap-07.pdf 
 
[table 1]organic and in organic form of rodenticide and shows the toxicity 
level and different mode of ingestion 
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Some of it changes the serum calcium level while some are toxic when 
inhaled.  Rodenticides are toxic when eaten or inhaled or when it comes in 
direct contact within skin.[4,5,6,7]  
 
picture[1]the poison is mostly intaken in three forms mainly by ingestion, 
inhalation and demal contact. Because of its different action the mode of 
treatment, complications and investigations varies. 
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Table 2. Summary of common rodenticides 
Rodenticide Type Chemical Class 
Days of feeding 
needed 
Warfarin Anticoagulant Hydroxycoumarin Multiple 
Chlorophacinone Anticoagulant Indandione Multiple 
Diphacinone Anticoagulant Indandione Multiple 
Bromadiolone Anticoagulant Hydroxycoumarin Single 
Difethialone Anticoagulant Hydroxycoumarin Single 
Brodifacoum Anticoagulant Hydroxycoumarin Single 
Bromethalin Non-anticoagulant Other Single 
Cholecalciferol Non-anticoagulant Vitamin D3 Multiple 
Zinc phosphide Non-anticoagulant Other Single 
Strychnine Non-anticoagulant Other Single 
 
COUMARIANS AND INDANDIONES 
ii) INORGANIC RODENTICIDES 
a) Thallium sulphate 
b) Yellow phosphorous 
c) Zinc phosphide 
d) Strychinne 
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e) Sodium fluoroacetate and fluoroacetamide 
f) Aluminium phosphide. 
Miscellaneous Rodenticides 
Red Squill and Cholecalciferol 
COUMARIANS AND INDANDIONES The most commonly used 
toxic  Rodenticides are warfarin derivatives. The first Rodenticide action was 
anticoagulant by warfarin 1950 and it was registered to use. 
Warfarians are absorbed by the gastrointestinal track, and also across 
the skin. The normal cogulation  path way are seen below: 
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This picture shows the normal clotting mechanism. The action of each 
factors both intrinsic and extrinsic pathway ,thrombus formation from 
thrombi 
Mechanism of Action 
Because of the coagulation, the normal haemostasis is maintained, 
platelets are accumulated and attached to the bleeding site 
 
Injury to the endothelium cause factor VII activated,  which activate  
X, then  it activates prothrombin  to thrombin, fibrinogen to firbin by 
thrombin. This fibrin stabilise the clot. 
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It suppresses the Vitamin K dependant clotting factor(II,VII, IX,X) in 
Liver. It increase the vascular permeability and causes internal haemorrhage. 
The effects can be seen few days later because of the long half-lives of the 
Vitamin K dependent clotting factor. Even  small dosage can be more 
toxic.[2,3]  
 
Molecular form of warfarin, coumarin 
It prolongs the Prothrombin time. The duration takes within 24 hours 
to 36-72 hours.[8,9] Brodifacoum( super warfarin) can be more toxic, even if 
it is taken as low as 1 mg dosage in adults or 0.014 mg per kg in children.[2,3 
] Because of the long duration of the action of warfarin, Vitamin K has to be 
taken for a very long time with monitoring of the Prothrombin time.[10] A 
study shows that, warfarin toxic patient  presented in unconscious  state even 
after two weeks later due to the massive intra cerebral haemorrhage[11].   
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ROLE OF VITAMIN K AGAINST WARFARIN 
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Vitamin K role in coagulation pathway. It act as a anticoagulant and 
warfarin block the clotting  mechanism in blood... 
 
 
It is available in both cake and powder form and the mechanism of 
action is same in both of the content. 
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Treatment : In managing the anticoagulant derivatives over dosage 
Monitor :     1. Liver function test 
                    2. Prothrombin time 
                    3. International normalised ratio 
                    4. Complete blood count 
                    5. Monitor vitamin K dependent clotting factors 
vitamin K is treatment of choice based on prothrombin time for 
prolong bleeding, vitamin K  can be given in infusion either with dextrose or 
normal saline 
If the INR less than 2 it is unnecessary to start treatment. 
1) STOMACH WASH:  It will be useful within 60 minutes of the intake, 
after that there will be no role of action. The nasogasttric tube inserted 
in nose and stomach wash done by suction using water. All the content 
will be washed away after  60 minutes  will be adsorbed [45] 
2) CONTRAINDICATIONS : Risk of haemorrhage, corrosive 
poisoning, hydrocarbons 
3) CHARCOAL : charcoal can be given along with stomach wash   
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ROLE OF WARFARIN TOXICITY IN BLOOD WARFARIN 
INTERFERE WITH CLOTTING MECHANISM 
The initial presentation of warfarin toxicity within 24 hours have 
normal Prothrombin time. It takes to prolong after 48 hours [12] So 
monitoring  is necessary  for two to three weeks in certain cases. 
  
  
 
Treatment: 
Antidote 
Phytonadione:  
Neither Vitamin 
Dosage of phytonadione(oral)
• Adults and children over 12 years: 15
• Children under 12 years: 5
Aquamephyton ( colloidal phytonadione)
Adults and children over 12 years
Children under 12 years
The patients should be monitored for 5
16 
K3(menadione) or Vitamine K4(menadiol)
 
-25 mg 
-10 mg 
 (intra muscular) 
 :  5-10mg 
   : 1-5 mg 
-10 days after ingestion.
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Higher dose of anticoagulant can be treated with 100 mg for longer 
duration more than month.[44] 
INORGANIC RODENTICIDES 
a) Thalium  
Thallium sulphate is mostly intaken by the guts and across the skin. 
These components are mostly excreted in the kidney and liver. The half-life 
of Thallium is 1.9 days in blood. In humans LD50 is between 10 and 15 mg 
per kg[13]. 
The clinical presentation takes 24 hours to 48 hours  in high dosage 
and the neurological manifestation takes 2-5 days after ingestion. The main 
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cause of the  death in thalium toxicity is by respiratory failure and cardiac 
arrest[14]  
 
Mechanism of action of Thallium: 
It causes ribosomal damage and riboflavin  sequestration. It blocks the 
potassium dependent channel and interfere with myelin sheath 
It damage the oxidative phosphorylation by attach to the sulphydryl 
group in mitochondria block the respiratory cycle. 
Treatment: 
Initial stomach wash should be given, then activated charcoal to absorb 
the content, ferrocyanide also tried. 
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PHOSPHORUS: 
Phosphorus available in different forms yellow phosphorus, white 
phosphorus, combine with zinc, aluminium 
YELLOW  PHOSPHORUS 
 
Phosphorous in various form-yellow, red, and violet it could not seen 
in earth because it is a free element  
Phosphorous its autonomic number-15, is available in different 
forms.[32] Because of its organo phosphorous compounds it is used as 
Rodenticide. Inorganic phosphates come under  non toxic group[33] 
COMPLICATION IN GENERAL – PHOSSY JAW 
Long duration of exposure to white phoshorous leads to tissue death  
around jaw. The complaints will be jaw swelling and tooth ache. Colour 
changes will happen[35,36] 
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White phosphorous consumption produce smoking stool syndrome. 
[34] For that toxicity before they used copper sulphate for it later found that 
the patient showed kidney and brain toxicity. Phosphorous combine with zinc 
,aluminium and various molecules, each one of that caries specific role . 
ALUMINIUM PHOSPHIDE: 
It affects the cardiovascular system in the form of myocarditis and also 
affects other major organs [37].It is more toxic. 
For treatment, magnesium sulphate is used.[38] Patients admitted 
within 4 hours gastric lavage can be tried, later potassium permanganate is 
used in the ratio of (1;10,000) .Finally will  go for haemodialysis. 
The presentation will be late onset so monitor up to or beyond 72 hours 
is indicated[42]  
  
  
 
MECHANISM OF ACTION OF ALUMINIUM PHOSPHIDE
 
INHIBIT CYTOCHROME C IN MITOCHONDRIA
 
CELLULAR RESPIRATORY DAMAGE
 
 
                                         
OXIDATIVE STRESS WITHIN 48 HOURS
REDUCTION OF H2O2
DECREASE CATALASES
21 
AIP+H2O=AL (OH) 3+PH3 
ALP+HCL=ALCL3+PH3 
 
RESOLVE WITH IN 5 DAYS
= O2+H2O
INCREASE SUPEROXIDE DISMUTASE
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TREATMENT OF ALUMINIUM PHOSPHIDE 
 
  Studies shows that N-acetyl cysteine used as a antidote for 
rodenticide poisoning especially aluminium phosphide and zinc 
phosphide[47] 
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NAC helps to maintain the glutathione level  for maintainance of micro 
circulation, and major role in inotropes. It interfere with inflammatory 
process [48,49] 
It can be used in person who is not a candidate for liver transplant; 
DOSAGE OF NAC:  
150mg/kg for the first 60 minutes then the dose is reduced to 50mg/kg 
for four hours, then 100mg/kg  for sixteen hours 
 
ROLE OF NAC INCREASE THE GLUTATHIONE 
YELLOW PHOSPHOROUS: 
Yellow phosphorous is quite difficult to treat. It is also known as white 
phosphorous. It is more volatile and acts as a corrosive agent . It also causes 
damage to the skin and tissues. The first presentation of the toxicity is 
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Vomitting and severe throat with abdominal pain. It is available in powder, 
paste form. 
 
 
 
PHOSPHOROUS IN PASTE AND  POWDER FORM 
They may also have blood vomiting.[15] 
The more intake of the yellow phosphorous also causes a kind of garlic     
smell in patients [16,17]. It also affects various system of the body.  
In end stage liver disease liver transplant is main stay of treatment  the 
clinical presentation of it is divided in to :                 
Stage First : clinical presentation starts in a period of 24 hours-
asymtomaticphase. 
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Stage Second: clinical manifestation will be occur between 24-48 
hours- symptomatic phase 
Stage Third : later 72 hours causes death [24] 
CRITERIA FOR LIVER TRANSPLANT IN ACUTE LIVER FAILURE 
BY  NON ACETAMINOPHEN TOXINS 
INR >6.5(regardless of hepatic encephalopathy) OR 3 OUT OF 5     
1. AGE <10 OR>40 YEARS 
2. ETIOLOGY INDETEMINANTE DRUG INDUCED 
3. TIME INTERVAL FROM CTERUS TO ENCEPHALOPATHY >7     
     DAYS         
4. INR 3.5 
5. BILLIRUBIN 17.6md/dl    
ZINC PHOSPHIDE 
It is less corrosive agent and less toxic than yellow phosphorous. The 
inhalation of the zinc phosphorous causes pulmonary edema. The main cause 
of death in Zinc phosphide is cardiomyopathy and shock due to the 
ventricular arrhythmias [16,18] 
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TOXICITY CLASSIFICATION - ZINC PHOSPHIDE/PHOSPHINE 
 
High Toxicity Moderate Toxicity Low Toxicity 
Very Low 
Toxicity 
Acute Oral 
LD50 
Up to and 
including 50 
mg/kg  
(≤ 50 mg/kg) 
Greater than 
50 through 
500 mg/kg  
(>50-500 
mg/kg) 
Greater than 
500 through 
5000 mg/kg  
(>500-5000 
mg/kg) 
Greater than 
5000 mg/kg  
(>5000 
mg/kg) 
Inhalation 
LC50 
Up to and 
including 0.05 
mg/L  
(≤0.05 mg/L) 
Greater than 
0.05 through 
0.5 mg/L  
(>0.05-0.5 
mg/L) 
Greater than 
0.5 through 2.0 
mg/L  
(>0.5-2.0 
mg/L) 
Greater than 
2.0 mg/L  
(>2.0 mg/L) 
Dermal 
LD50 
Up to and 
including 200 
mg/kg  
(≤200 mg/kg) 
Greater than 
200 through 
2000 mg/kg  
(>200-2000 
mg/kg) 
Greater than 
2000 through 
5000 mg/kg  
(>2000-5000 
mg/kg) 
Greater than 
5000 mg/kg  
(>5000 
mg/kg) 
Primary 
Eye 
Irritation 
Corrosive 
(irreversible 
destruction of 
ocular tissue) or 
corneal 
involvement or 
irritation 
persisting for 
more than 21 days 
Corneal 
involvement or 
other eye 
irritation 
clearing in 8 - 
21 days 
Corneal 
involvement or 
other eye 
irritation 
clearing in 7 
days or less 
Minimal 
effects 
clearing in 
less than 24 
hours 
Primary 
Skin 
Irritation 
Corrosive (tissue 
destruction into 
the dermis and/or 
scarring) 
Severe 
irritation at 72 
hours (severe 
erythema or 
edema) 
Moderate 
irritation at 72 
hours 
(moderate 
erythema) 
Mild or 
slight 
irritation at 
72 hours (no 
irritation or 
erythema) 
he highlight, Office of Pesticide Programs, Label Review Manual,:  
  
 
b) stychinne(nus vomica)
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The main presentation of the poison is convulsion. The presentation 
takes within 15-20 minutes after ingestion. In humans, the half
toxins is 10 hours. The toxic dosage is 15
15mg may be toxic to children[19]
Mechanism of Action 
In the spinal cord, the strychnine affects by firing the nerve cell which 
cause muscle spam. It also depends on the amount of dosage given.
IT BLOCK THE POST SYNAPTIC NERVE TERMINAL, AND 
DECREASE THE NERVE CONDUCTION
 
28 
-100 mg. Even the low dose of 
 
 
-life of  the 
 
 
 
  
 
TREATMENT: 
1. Activated choarcoal
2. Anticonvulsants(diazepam and phenobarbitol)
3. Muscle relaxants(dantrolene )
SODIUM FLUOROACETATE AND FLUOROACETAMIDE
 
MOLECULAR FORM OF 
FORMULA C2H4FNO IT BLOCK THE CITRIC ACID CYCLE
The main route of abs
acidosis and electrolyte imbalance which are the poor prognostic factors.
The neurological manifestation of sodium fl
convulsion and spasms[20]
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FLUROACETAMIDE.CHEMICAL 
orbtion is through the gut. It cause metabolic 
uoroacetate is 
 
 
 
 
 
tonic clonic 
  
30 
 
Mechanism of actions 
The molecule of fluoroacetate is converted to fluorocitrate in liver and 
it blocks the enzyme action in tricarboxylic acid ( Krebs) cycle. It also 
interferes with the cellular respiration. The main organs involved are kidney, 
brain and heart. 
TOXIC DOSE:  
The mechanism of action starts after 2 to 20 hours the toxic dose of 
sodium fluroacetamide are 13 to 14 mg /kg. and the fluroacetate will be 3 to 7 
mg/kg. 
Symptomatic treatments 
BARIUM: 
BARIUM CARBONATE:   
          It is one of the rodenticide poisoning in practise.  Its action upon 
muscle 
          It causes increase in intracellular potassium level and decrease the 
serum potassium level, it act as a depolarize action. The toxic dose will be 20 
to 30 mg /kg .Its action will start after 2 to 8 hours 
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          In north India it is used widely as rodenticide,[51] due to decrease 
extracellular potassium and turn off the sodium potassium ATPase 
meachanism[50].Normal serum blood level is 0.08 to 0.4mg/L. 
TREATMENT” 
 1. Stomach wash 
 2. Potassium supplement 
MISCELLANEOUS RODENTICIDES 
Red Squill 
 Red Squill is not a much used Rodenticide, as normally the mammals 
and other rodents will vomit immediately when intaken due to its intense 
nauseant property. So they do not retain the poison. The glycosides are also 
not absorbed by the guts efficiently, and even some of the absorbed 
glycosides are excreted quickly. Usually the glycosides causes cardiac 
impulse conduction and arrhythmias. 
TREATMENT 
 Red squill does not affect much when given in low dosage. If it is 
taken more, syrup like ipecac is given, which initiates vomiting. We should 
also monitor cardiac status electrocardiographically. 
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CHOLECALCIFEROL 
 The toxic effect of Cholecalciferol shows actions on liver, kidney and 
myocardium. The toxicities increase the serum calcium level and it cause 
poly urea, polydipsia, proteinuria by tubular injury in kidney which is the 
main cause of death. 
 
PICTURE SHOWS THE MEACHANISM OF VITAMIN D3  
AND IT CAUSES RENAL DAMAGE 
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TREATMENT 
          The role of treatment is to decrease the intestinal absorbtion and 
increase the excretion, so that there will be a decreased level of calcium in the 
blood. Usually charcoal is given every fourth-hourly  to increase the 
intestinal absorption. 
 Adequate hydration. 
 This is mainly done to increase the calcium level in urine. Monitoring 
of the electrolytes is necessary in the process.  
 Diuretic- It is given with the dose of 20-40 mg intravenously or 40-120 
mg orally 
 Steroid-Oral glucocorticoids is given with a dose of 1mg per kg and 
maximum of 20 mg per day. 
 Calcitonin- It acts as a antidote and it is rarely used.[21] Dose of 4 
international units per kg body weight every twelth-hourly in subcutaneous or 
intra muscular injection. It is continued for 2-5 days. 
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TREATMENT BASICS 
 Regularly we need to look for the container, and according to the 
product consumption we can start treatment. If the products not available we 
have to do symptomatic treatment. 
 1) In unstable patients we have to provide  airway 
 2) If BP is low, need to start ionotropes 
 3) Routine Investigations should be done to see the renal functions and 
liver functions  
 4) Coagulation profile should be done 
 5) All patients to avoid the intestine absorbtion, activated charcoal is 
given via nasogastric tube. It should start in 24 to 28 hours then only will be 
good result. To prevent the adverse reaction ,this procedure should be 
routinely done. 
    The dosage of charcoal taken 100 to 1000mg drug per gram. With 
water it  is not diluted 
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 6) Some time need we may need transfusion, in case of hemolysis 
poison like zinc phosphide which release phosphine gas. 
 7) Chelation therapy in heavy metal poisons. Examples Thallium and 
Arsenic. 
 8) In case of renal toxic, hemodialysis should be done. 
 9) In patients with coagulopathy ,Vitamin K need to start with monitor 
PT/INR. 
 Clinical presentations and change in the Bio chemical parameters. 
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Renal  Involvement 
a) Bromadiolone: Study shows that even a single dose cause 100% 
mortality. After 6 hours of ingestion it causes increased concentration 
of toxic debris. After 12 hours, the toxic debris  are deposited in the 
tubules. Afer 24 hours, this toxic debris destroy and cause necroses of 
tissues.[22]  
 
NORMAL KIDNEY 
 
KIDNEY AFTER  6 HOURS OF INGESTION 
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KIDNEY AFTER 24 HOURS OF INGESTION 
b) Thallium: It causes tubular damage, so monitoring of urine sediment 
and  urine albumin to find out early damage of renal involvement 
c) Cholecalciferol:   Increases the protein , red cell and white cell in the 
urine                             
d) Yellow phosphorus: Most frequent presentation was decreased urine 
ouput because of  the damage of renal tubules by deposition of toxic 
granules and bilirubin in tubules.  
 
e) Vacuolar degeneration of kidney after yellow phosphorous intake.                                                                               
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Hepatic Involvement 
a) Bromadiolone: After 12 hours of ingestion, it cause feathery 
degeneration of the liver. After 6 hours it causes toxic debris to deposit 
and cell death. After 24-48 hours, it causes high damage to the liver 
cell. 
 
               NORMAL LIVER WITH NORMAL ARCHITECTURE 
 
LIVER 6 HOURS AFTER INGESTION DESTRUCTION  
OF LIVER ARCHITECTURE 
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LIVER 48 HOURS AFTER INGESTION 
b) Thallium: It mainly causes hepatic damage and elevated liver enzymes. 
c) Yellow phosphorous: The presentation will be hepatomegaly and      
jaundice acute fulminant hepatitis, caogulopathy and hepatic 
encephalopathy. Liver biopsy shows steatohepatitis[30,31] and tissue 
necrosis. 
 
THE APPEARANCE WILL BE VACUOLAR IN LIVER CELL 
AFTER YELLOW PHOSPHOROUS INGESTION. IT CAUSES 
PIECEMEAL NECROSIS 
  
40 
 
 
FAT GLOBULES DEPOSITED IN LIVER 
d) Aluminiumphosphide: Higher dose affects the hepatic functions and 
jaundice will be presentations. 
GASTROINTESTINAL TRACT: 
a) Warfarin derivatives: Due to its prolongation of prothrombin time it  
causes hematemesis, malena, vomiting and abdominal pain.  
b) Thallium:  The main stay of presentation was nausea, vomiting  and  
abdominal pain. 
c) Bloody diarrhoea is also one of the presentation clinically in 
thallium toxic patients, stomatitis  and salivation, the involvement 
of  ileus  in last stage . 
  
  
41 
 
CENTRAL NERVOUS SYSTEM 
a) Thallium:  Main clinical presentation is paresthesia , it may or may not 
be associated with gastrointestinal involvement.[23] Neurological 
involvement and its severity is accessed by  involvement of myoclonic 
jerk, seizures, delirium and coma. 
b) Yellow phosphorous: Irritation, lethargy and restlessness, 
hallucinations and psychosis  are the  first clinical presentation of 
phosphorous .and finally delirium ,coma and death.  
c) Sodium fluroacetate and Fluroacetamide:    Spasmodic convulsions 
may be due to electrolytes involvement, involuntary movements due to 
cerebellar dysfunction   which   finally leads to depression and coma. 
Also death occurs due to asphyxia. 
d)  Strychnine: Clinical presentation will be seizures due to its increase    
neuronal action.        
e) Crimidine: After thirty minutes of the intake, its clinical  signs starts 
and the involvement will be involuntary movements ,convulsions, 
spasm  of limbs. 
f) Aluminium phosphide : 
 Neurological manifestations leads to altered sensations, 
involuntary movements, double vision. All these complaints progress 
to weakness of limbs, seizures episodes and coma.  
  
 
g) Barium carbonate: 
It cause acute quadriparesis and absence of reflex autonomic 
dysfunction, involuntary movements,
confusion , dilatation 
Left side picture 
side picture shows that low count of potassium  produce abno
depolarization. 
HEAMATOLOGY:   
a) Yellow phosphorus :Study shows that it can cause
bonemarrow suppression leads to myeloid this complication occur in 
second stage[26,27]
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 trismus, myoclonus,
 of pupil[53]. 
shows that the normal potassium level in ECF,
 
 
 
 
 headache, 
 
 right 
rmal 
neuropenia and 
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CARDIOVASCULAR SYSTEM: 
a) Yellow phosphorous: It causes tachycardia, arrhythmia, and 
hypotension which leads to toxic . Studies shows that the toxic 
manifestation leads to long term left ventricular dysfunction by 
decreasing the compliance of heart ,so monitoring ECG and Echo in 
high toxic patients. 
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b) Thallium: The first presentation will be hypotension ,arrhythmia  
and the late presentation will be hypertension due to its 
vasoconstriction action. 
c) Aluminium Phosphide:  After intake of aluminium phosphide, it  
produce cardiac failure by damaging the myocytes which leads to 
cardiomyopathy[39], volume loss and play role on adrenal  
destruction[40].The symptom shows chest pain . 
 Patients highly need inotropic supports due to refractory hyotension. 
Brugada pattern in ECG due to electrolyte imbalance of pottasium [43] 
ECG SHOWS THE WIDE QRS AFTER THE POISON INTAKE,  
IT RECOVERS IN LATER STAGE 
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D.BARIUM CARBONATE: 
 It causes tachycardia, main role on rate activity finally leads to 
arrhythmia, in ECG ST changes occur, one of the clinical manifestation was 
hypertension.[52]  
 
Mechanism of barium in depolarization and the mechanism of 
hypokalemia the value of potassium coming down with barium, and their 
recovery after 24 hours of treatment. 
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PICTURE SHOWS THAT DUE TO LOW K IN BLOOD,CAUSE 
ELECTROLYTES IMBALANCE AND  CONTRACTION, 
EXCITABILITY 
 
 
 
 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
 This  study has been done at the toxicology ward of Madras Medical 
College, Rajiv Gandhi Govt. Hospital Chennai. 
STUDY PERIOD: 
 6 months 
STUDY DESIGN: 
 Observational Study 
ETHICAL COMMITTEE APPROVAL: 
 For this study Approval has been obtained from the Ethical Committee. 
INCLUSION CRITERIA: 
 All patients aged >= 13 years 
EXCLUSION CRITERIA: 
 Patients with multiple compound ingestion. 
 Patient on antiplatelets or oral anti-coagulants. 
 Patients with previous major systemic illness. 
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CONSENT: 
 This study group thus identified by the above criteria( Inclusion and 
Exclusion criteria) was first explained and informed about the nature of the 
study. Those participants who accepted were taken up for this  study with 
their written consent from the participants or their relatives in their respective 
languages. 
STUDY SUBJECTS: 
 Those patients who fulfilled the inclusion criteria, which is above 13 
years of age and both the genders have involved in this study. Those  
involved patients were completely examined, including their history and the 
necessary investigations were also taken. 
 The information, regarding the type and the amount of rodenticide 
consumed were taken from the patients and their relatives. 
DEFINITIONS AND REFERENCE LAB VALUES USED IN THE 
STUDY: 
HE(Hepatic Encephalopathy): 
 It is found in Patients with Chronic Liver disease. It is a reversible 
neurological disorder. 
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AKI(Acute Kidney Injury): 
 Increased Serum Urea and Creatinine Concentration, which often leads 
to decrease in Urine Output. 
ARDS(Acute Respiratory Distress Syndrome): 
 Decrease in Oxygen Saturation and bilateral pulmonary infilteration, 
which 8presence of bilateral alveolar or interstitial infiltrates in Chest X-Ray 
and PCWP less than 18mmHg . No evidence of  Left Atrial enlargement. 
CBC(Complete Blood Count): 
TC(Total Count): 
 Normal  4300-10,800 cells/cmm 
 HB(Haemoglobin)  13-18gm/dl(male), 12-16 gm/dl(female) 
 PLTS(Platelet Count) - 15,0000-40,0000/cmm 
 PT/INR(Prothrombin Time/ International Normalised Ratio)-  12-13 
sec/0.8-1.2 
 BT/CT(Bleeding Time/Clotting Time) –Less than 9 minutes 
RFT(Renal function Test): 
 Urea  20-40 mg/dl 
 Serum Creatinine 0.5-1.2 mg/dl(male), 0.4-1.1 md/dl(female) 
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 Sodium   135-145 mEq/l 
 Potassium  3.5-5.1 mEq/l 
 Bicarbonate  22-28 mEq/l 
 Chloride   98-108 mEq/l 
LFT(Liver function Test): 
 Serum Total Bilirubin -1.0 and 1.5 mg/dl 
 Serum Transaminase<30 U/L for men and <19 U/L for women. 
CT(Computed Tomography) 
 
  
  
 
OBSERVATION  
AND  
RESULTS 
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OBSERVATIONS AND RESULTS 
 
 
1) Age :  < 20& 20 to 40 & 40 to 60 & >60 - Results ( 20 to 40 Age  
Increased Number of patients ) 
 
age_group 
 
 
 
Frequency Percent 
Valid 
20-40 yrs 98 65.3 
41-60 yrs 36 24.0 
above 61 yrs 16 10.7 
Total 150 100.0 
 
 
Frequenty admitted patients in age between 20 – 20 years.98 patients 
are in this age group, it come around 65.3%.above 61 years 16 people are 
counted.36 patients from 41 to 60 years(24 %). 
65%
24%
11%
Age group
20-40 yrs
41-60 yrs
above 60 yrs
  
 
2) sex : Female is more than male 
 
 
 
 
Valid 
 
 
57%  are female 
In our study more
in higher percentage. C
 
57%
52 
 
SEX 
Frequency Percent
Male 65 43.3
Female 85 56.7
Total 150 100.0
and 43.3% are male  
 number of female patients were involved,
ompared with female , male are lesser in number.
43%
Gender
 
 
 
 
 
 they come 
 
Male
Female
  
 
3) Content : powder > bait
 
 
 
Valid 
Powder
Paste
Total
 
          This picture shows the comparative
are more consumed. In this study shows that powder are more consumed by 
the people followed by bait then paste.52% are powder uptake,27% are bait 
uptake, 21% are bait 
0%
10%
20%
30%
40%
50%
60%
Bait
27%
53 
  > paste  
Content 
Frequency 
Bait 40 
 78 
 32 
 150 
 chart as in which form of poison 
Powder Paste 
52%
21%
Series 1
Percent 
26.7 
52.0 
21.3 
100.0 
 
Bait
Powder
Paste 
  
 
4) Duration : 0 to 6 HRS & 6 to 12 HRS & 24 to 72 HRS & 3 TO 7 
DAYS & 7 TO 14 DAYS
 
 
Valid 
0-
6-12 hrs
12-
24-
3-7 days
7-14 days
Total
 
 In our study more number patients reach the hospital for medical care 
in 24 hours 67% come under this group then 12%  are from 6 
lesser number of patients in 0
0%
10%
20%
30%
40%
50%
60%
70%
0-6 hrs 6-12 hrs
4%
12%
54 
 
 
DURATION 
Frequency 
6 hrs 6 
 18 
24 hrs 15 
72 hrs 101 
 5 
 5 
 150 
-6 hours and 3 -7 days 
12-24 hrs 24-72 hrs 3-7 days 7-14 days
10%
67%
3% 3%
Duration
Percent 
4.0 
12.0 
10.0 
67.3 
3.3 
3.3 
100.0 
 
-12 hours  
0-6 hrs
6-12 hrs
12-24 hrs
24-72 hrs
3-7 days
7-14 days
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5) DOSE : 5 TO 30 G & 30 TO 50 G & > 50 G 
 
 
DOSE_SCORE 
 
 
 Frequency Percent 
Valid 
5-30 Grams 117 78.0 
31-50 grams 20 13.3 
Above 50 grams 13 8.7 
Total 150 100.0 
 
 
patients are classified according to their amount of consumption .78% 
uptake 5 to 30 grams,13%31-50 grams.9% are above 50 grams which 
produce more complications 
 
78%
13%
9%
Dose
5-30 Grams
31-50 Grams
Above 50 Grams
  
 
DOSE_SCORE * DEATH CROSSTABULATION
 
 
d
o
se
_
sco
re
 
5-30 Grams 
31-50 grams 
Above 50 grams 
Total 
Chi square = 112.912* p<0.001
 
Death related to amount of consumption of rodenticide poisoing
 When intake of more than 50 grams 77% death rate.inkake of 5 grams 
not produce much complications
0%
20%
40%
60%
80%
100%
120%
5-30 Grams
100%
0%
56 
DEATH
Alive DEATH
Count 117 
% within dose_score 100.0% 0.0%
% within DEATH 83.6% 0.0%
Count 20 
% within dose_score 100.0% 0.0%
% within DEATH 14.3% 0.0%
Count 3 
% within dose_score 23.1% 76.9%
% within DEATH 2.1% 100.0%
Count 140 
% within dose_score 93.3% 6.7%
% within DEATH 100.0% 100.0%
 
 
31-50 Grams Above 50 Grams
100%
23%
0%
77%
 
 Total 
 
0 117 
 100.0% 
 78.0% 
0 20 
 100.0% 
 13.3% 
10 13 
 100.0% 
 8.7% 
10 150 
 100.0% 
 100.0% 
 
 
DEATH
Alive
  
 
6)  MORTALITY CHART : PASTE DEATH MORE IN PASTE FORM 
 
CONTENT_ * DEATH CROSSTABULATION
 
 
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
    Pearson Chi-Square 
 
From this study,
this substances and 20%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Alive 
27%
56%
17%
57 
DEATH 
Alive  death
Count 38 2 
% within 
DEATH 27.1% 20.0%
Count 78 0 
% within 
DEATH 55.7% 0.0%
Count 24 8 
% within 
DEATH 17.1% 80.0%
Count 140 10 
% within 
DEATH 100.0% 100.0%
23.036* p<0.001 
 paste content produce more toxicity, 
 from bait form. 
death
20%
0%
80%
 
 
Total 
 
40 
 26.7% 
78 
 52.0% 
32 
 21.3% 
150 
 100.0% 
 
80% death from 
Paste
Powder
Bait
  
 
ARRHYTHMIA IN_ECG * CONTENT_ CROSSTABULATION
 
 
A
R
R
TH
Y
M
IA
_IN
_ECG
 
Absent 
Count
% within 
ARR
ECG
% within Content_
Present 
Count
% within 
ARR
ECG
% within Content_T
otal
 
Count
% within 
ARR
ECG
% within Content_
Chi square = 3.377 p>0.05 (0.185) NS
 
From 10 patients 80% are p
those patients came with powder intake 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Absent
28%
50%
22%
58 
Content_
Bait Powder 
 39 70 
HYTHMIA_IN_
 
27.9% 50.0% 
 97.5% 89.7% 
 1 8 
HYTHMIA_IN_
 
10.0% 80.0% 
 2.5% 10.3% 
 40 78 
HYTHMIA_IN_
 
26.7% 52.0% 
 100.0% 100.0% 
 
resented  with arrhythmia in ECG
 whereas 10% from bait and paste
Present
10%
80%
10%
 
 Total 
Bait 
31 140 
22.1% 100.0% 
96.9% 93.3% 
1 10 
10.0% 100.0% 
3.1% 6.7% 
32 150 
21.3% 100.0% 
100.0% 100.0% 
 
 and all 
 
Paste
Powder
Bait
  
 
Content_ * FEVER_ 
 
 
 
 
Content_ 
Bait % within FEVER_
Powder % within FEVER_
Paste % within FEVER_
Total % within FEVER_
Pearson Chi-Square= 
 
 Fever- 20% from bait intake ,70% from powder intake and 10%
paste substance. 
 
0%
20%
40%
60%
80%
100%
Absent
27%
51%
22%
59 
CROSSTAB 
FEVER_ 
Absent Present
Count 38 2
 27.1% 20.0%
Count 71 7
 50.7% 70.0%
Count 31 1
 22.1% 10.0%
Count 140 10
 100.0% 100.0%
1.491 p=.474 NS 
 
Present
20%
70%
10%
Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
 from 
Paste
Powder
Bait
  
 
 
 Most common presentation is abdominal pain.60% people from 
powder consumption, 
study, vomiting is more common in powder consumption 
0%
20%
40%
60%
80%
100%
Absent
37%
40%
23%
 
Content
_ 
Bait 
VOMITING_
Powde
r VOMITING_
Paste 
VOMITING_
Total Pearson 
Chi-Square=
 6.707*  
p<0.05 S 
 
VOMITING_
60 
VOMITING - CROSSTAB 
 
20% are in bait group and 20% from paste. In our 
  
Present
20%
60%
20%
VOMITING_ 
Absent Present 
Count 22 18 
% within 
 
36.7% 20.0% 
Count 24 54 
% within 
 
40.0% 60.0% 
Count 14 18 
% within 
 
23.3% 20.0% 
Count 60 90 
% within 
 
100.0% 100.0% 
 
Paste
Powder
Bait
Total 
40 
26.7% 
78 
52.0% 
32 
21.3% 
150 
100.0% 
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CROSSTAB 
 
 
 
 
 
 
 
 
 
HEMATEMESIS Total 
Absent Present 
Content_ 
Bait 
Count 16 24 40 
% within 
HEMATEMESIS 
14.5% 60.0% 26.7% 
Powder 
Count 76 2 78 
% within 
HEMATEMESIS 
69.1% 5.0% 52.0% 
Paste 
Count 18 14 32 
% within 
HEMATEMESIS 
16.4% 35.0% 21.3% 
Total 
Count 110 40 150 
% within 
HEMATEMESIS 
100.0% 100.0% 100.0% 
Pearson Chi-Square=
 50.674* 
p<0.05 1 S 
 
5% patients from 
powder, 35% in 
paste 60% in bait 
    
  
 
Persons consumed bait,
which 14 of them consumed paste
0%
20%
40%
60%
80%
100%
Absent
15%
69%
16%
62 
 
 
 
HEMETEMESIS 
 
 
 24 patient presented with  hemetemesis in 
 
 
 
 
 
 
 
 
 
 
 
Present
60%
5%
35%
 
 
Paste
Powder
Bait
  
 
 
35 patients from paste,
0%
20%
40%
60%
80%
100%
Absent
15%
69%
16%
 
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
Pearson Chi-Square=
 50.674* p<0.05 
1 S 
63 
MALENA 
 
 
 
 60% from bait , remaining 5 % from powder.
Present
60%
5%
35%
MELENA 
Absent Present
Count 16 24
% within 
MELENA 14.5% 60.0%
Count 76 2
% within 
MELENA 69.1% 5.0%
Count 18 14
% within 
MELENA 16.4% 35.0%
Count 110 40
% within 
MELENA 100.0% 100.0%
  
 
 
Paste
Powder
Bait
Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
  
  
 
Totally 10 patients presented with hematuria,
powder consumption and 
0%
20%
40%
60%
80%
100%
Absent
26%
51%
23%
 
Content_ 
Bait 
Count
% within 
HEMATURIA
Powder 
Count
% within 
HEMATURIA
Paste 
Count
% within 
HEMATURIA
Total 
 
 
Count
% within 
HEMATURIA
Chi
p<2.23N S
64 
CROSS TAB 
 
 
HEMATURIA 
 
 
 in which 70% from 
30% from bait 
 
Present
30%
70%
0%
HEMATURIA
Absent Present
 37 
 
26.4% 30.0%
 71 
 
50.7% 70.0%
 32 
 
22.9% 0.0%
 140 
 Pearson 
-Square= 2.998  
 
100.0% 100.0%
 
Paste
Powder
Bait
 Total 
 
3 40 
 26.7% 
7 78 
 52.0% 
0 32 
 21.3% 
10 150 
 100.0% 
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 CROSS TAB  
 
Gum bleed: powder 70% ,bait 20%, 10%paste 
7 patients in powder,2  patients in bait, 1 patients in paste 
140 patients without any complaints 
 
 
 
 
 
 
 
 
 
 
 
 GUMBLEED Total 
Absent Present 
Content_ 
Bait 
Count 38 2 40 
% within 
GUMBLEED 27.1% 20.0% 26.7% 
Powder 
Count 71 7 78 
% within 
GUMBLEED 50.7% 70.0% 52.0% 
Paste 
Count 31 1 32 
% within 
GUMBLEED 22.1% 10.0% 21.3% 
Total 
Count 140 10 150 
% within 
GUMBLEED 100.0% 100.0% 100.0% 
  
 
Pearson Chi-Square= 
0%
20%
40%
60%
80%
100%
Absent
27%
51%
22%
0%
20%
40%
60%
80%
100%
120%
Absent
29%
48%
23%
66 
1.491 p= .474 NS 
 
 
 
 
 
Present
20%
70%
10%
Present
7%
87%
6%
 
 
Paste
Powder
Bait
Paste
Powder
Bait
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Totally 15 patients presented with abdominal pain, in which 13 patients 
from powder, 1 from bait and paste 
 
CROSSTAB 
 
  
 ABDOMINAL_ 
PAIN 
Total 
Absent Present 
Content
_ 
Bait 
Count 39 1 40 
% within 
ABDOMINAL_PAIN 
28.9% 6.7% 26.7% 
Powder 
Count 65 13 78 
% within 
ABDOMINAL_PAIN 
48.1% 86.7% 52.0% 
Paste 
Count 31 1 32 
% within 
ABDOMINAL_PAIN 
23.0% 6.7% 21.3% 
Total 
Count 135 15 150 
% within 
ABDOMINAL_PAIN 
100.0% 100.0% 100.0% 
Pearson Chi-
Squar8.032 p<0.05 
S 
Abdominal pain 
 
    
  
 
 
 
 
Pearson Chi-Square= 
Low level of blood potassium in powder in take.
powder 76%,bait 24%,paste 4%. 
 
 
0%
20%
40%
60%
80%
100%
120%
>3.5
 
Content
_ 
Bait 
Powder 
paste 
Total 
68 
8.048*p<0.001 
 
 
<3.5
28%
20%
47% 76%
25%
4%
POTASSIUM
>3.5 <3.5
Count 35 5
% within 
POTASSIUM 28.0% 20.0%
Count 59 19
% within 
POTASSIUM 47.2% 76.0%
Count 31 1
% within 
POTASSIUM 24.8% 4.0%
Count 125 25
% within 
POTASSIUM 100.0% 100.0%
 
Paste
Powder
Bait
 Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
  
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
 
Pearson Chi-Square 
10 had this complaints
40% in paste  and 0% in bait
 
 
0%
20%
40%
60%
80%
100%
Absent
29%
51%
20%
69 
CROSSTAB 
SEIZURES_
Absent Present
Count 40 0
% within 
SEIZURES_ 28.6% 0.0%
Count 72 6
% within 
SEIZURES_ 51.4% 60.0%
Count 28 4
% within 
SEIZURES_ 20.0% 40.0%
Count 140 10
% within 
SEIZURES_ 100.0% 100.0%
= 4.739 p= 0.094 N S 
, in that 60% in powder 
 
Present
0%
60%
40%
 Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
Paste
Powder
Bait
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Some patients presented with seizures 60% are in powder and 40% in paste 
 
CROSSTAB 
 ALTERED_SENS
ORIUM 
Total 
Absent Present 
Content
_ 
Bait 
Count 40 0 40 
% within 
ALTERED_SENSO
RIUM 
27.6% 0.0% 26.7% 
Powde
r 
Count 77 1 78 
% within 
ALTERED_SENSO
RIUM 
53.1% 20.0% 52.0% 
Paste 
Count 28 4 32 
% within 
ALTERED_SENSO
RIUM 
19.3% 80.0% 21.3% 
Total 
Count 145 5 150 
% within 
ALTERED_SENSO
RIUM 
100.0% 100.0% 100.0% 
Pearson Chi-
Square
 =10.743* 
p<0.05 S 
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CONTENT_ * ULTRASOUND_ABDOMEN CROSSTABULATION 
 
 ULTRASOUND_ABDOMEN Total 
CHOLE
CYSTITI
S 
FATTY 
LIVER 
NORMA
LSTUDY 
Conte
nt_ 
Bait 
Count 2 0 38 40 
% within 
ULTRASOUND_
ABDOMEN 
40.0% 0.0% 27.1% 26.7% 
Powd
er 
Count 3 4 71 78 
% within 
ULTRASOUND_
ABDOMEN 
60.0% 80.0% 50.7% 52.0% 
Bait 
Count 0 1 31 32 
% within 
ULTRASOUND_
ABDOMEN 
0.0% 20.0% 22.1% 21.3% 
Total 
Count 5 5 140 150 
% within 
ULTRASOUND_
ABDOMEN 
100.0% 100.0% 100.0% 
100.0
% 
 
Pearson Chi-Square=3.652 p>0.05 (0.455) 
80% in powder intake.140 patients have no changes and have normal study. 
20% in paste 
 
  
 
 
 
 
 
 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
CHOLECYSTITIS
40.00%
60.00%
0.00%
72 
 
FATTY LIVER
NORMALSTUDY
0.00%
27.10%
80.00%
50.70%
20.00%
22.10%
 
Paste
Powder
Bait
  
 
 
 
Bait 
Powder 
Paste 
Total 
 
Pearson Chi-Square = 1.969  p= 0.374 N S
5 patients had this complaints.
20% bait 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Absent
27%
51%
22%
73 
CROSSTAB 
HEADACHE
Absent Present
Count 39 1
% within 
HEADACHE 26.9% 20.0%
Count 74 4
% within 
HEADACHE 51.0% 80.0%
Count 32 0
% within 
HEADACHE 22.1% 0.0%
Count 145 5
% within 
HEADACHE 100.0% 100.0%
 
 
Present
20%
80%
0%
 Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
Paste
Powder
Bait
  
 
 
Content_ 
Bait WEEKNESS_OF_LIMBS
Powder WEEKNESS_OF_LIMBS
Paste WEEKNESS_OF_LIMBS
Total WEEKNESS_OF_LIMBS
 
145 people without complaints.
powder form 
Pearson Chi-Square = 4.772 p =0.092 N S
0%
20%
40%
60%
80%
100%
120%
Absent
27%
51%
22%
74 
CROSSTAB 
WEEKNESS_OF_LIM
BS_ 
Absent Present
Count 40 
% within 
_ 
27.6% 
Count 73 
% within 
_ 
50.3% 100.0%
Count 32 
% within 
_ 
22.1% 
Count 145 
% within 
_ 
100.0% 100.0%
5 patients had this manifestations. 5 in 
 
Present
0%
100%
10%
Total 
 
0 40 
0.0% 26.7% 
5 78 
 52.0% 
0 32 
0.0% 21.3% 
5 150 
 100.0% 
 
Paste
Powder
Bait
  
 
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
 
Pearson Chi-Square 
 
10 patients had this complaints,80% in paste form
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Absent
27%
51%
22%
75 
CROSSTAB 
JAUNDICE
Absent Present
Count 38 2
% within 
JAUNDICE 27.1% 20.0%
Count 78 0
% within 
JAUNDICE 55.7% 0.0%
Count 24 8
% within 
JAUNDICE 17.1% 80.0%
Count 140 10
% within 
JAUNDICE 100.0% 100.0%
= 23.036* p<0.05 S 
 and 20% in bait form
 
Present
20%
0%
80%
 
Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
 
Paste
Powder
Bait
  
 
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
Pearson Chi-Square = 2.288 p=03.19 NS
 
60% come under powder and
0%
20%
40%
60%
80%
100%
Absent
27%
51%
22%
76 
CROSSTAB 
OLIGURIA 
Absent Present
Count 40 0
% within 
OLIGURIA 27.6% 0.0%
Count 75 3
% within 
OLIGURIA 51.7% 60.0%
Count 30 2
% within 
OLIGURIA 20.7% 40.0%
Count 145 5
% within 
OLIGURIA 100.0% 100.0%
 
 
 40%in in paste form, 145 patients 
without any complaints 
 
Present
0%
60%
40%
Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
 
Paste
Powder
Bait
  
 
 
 
Content_ 
Bait 
Powder 
Paste 
Total 
Pearson Chi-Square =2.288 p=0.319 NS
60% from powder intake,40%
less than 40 urea value.
 
0%
20%
40%
60%
80%
100%
<40
27%
51%
22%
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CROSSTAB 
URIEA 
<40 >40
Count 40 
% within URIEA 27.6% 0.0%
Count 75 
% within URIEA 51.7% 60.0%
Count 30 
% within URIEA 20.7% 40.0%
Count 145 
% within URIEA 100.0% 100.0%
 
 
 in paste. 145 patients with normal value
 
 
>40
0%
60%
40%
Total 
 
0 40 
 26.7% 
3 78 
 52.0% 
2 32 
 21.3% 
5 150 
 100.0% 
 with 
 
Paste
Powder
Bait
  
 
 
 
Content_ 
Bait 
Count
% within CHEST 
PAIN
Powder 
Count
% within CHEST 
PAIN
Paste Count% withinCHEST PAIN
Total Count
% withinCHEST PAIN
 
Pearson Chi-Square 
10 patients develop chest pain, whereas the remaining 140 does 
0%
20%
40%
60%
80%
100%
Absent
29%
51%
20%
78 
CHEST PAIN 
Crosstab 
CHEST PAIN
Absent Present
 40 
 
28.6% 0.0%
 72 
 
51.4% 60.0%
 28 
 20.0% 40.0%
 140 
 100.0% 100.0%
= 4.739 p= 0.094 N S 
 
not produce any  chest pain. 
Present
0%
60%
40%
 
Total 
 
0 40 
 26.7% 
6 78 
 52.0% 
4 32 
 21.3% 
10 150 
 100.0% 
 
 
Paste
Powder
Bait
  
 
 
Content_ 
Bait 
CREATININE
Powder 
CREATININE
Paste 
CREATININE
Total 
CREATININE
 
Pearson Chi-Square =2.288 p=0.319 NS
lesser  amount increase in creatinine value.
0%
20%
40%
60%
80%
100%
Normal
27%
51%
22%
79 
CREATININE
0.6- 1 normal abnormal
Count 40 
% within 
 
27.6% 
Count 75 
% within 
 
51.7% 60.0%
Count 30 
% within 
 
20.7% 40.0%
Count 145 
% within 
 
100.0% 100.0%
 
 not much elevation seen
 
 
 
Abnormal
0%
60%
40%
 Total 
 
0 40 
0.0% 26.7% 
3 78 
 52.0% 
2 32 
 21.3% 
5 150 
 100.0% 
 
 
Paste
Powder
Bait
  
 
CONTENT_ * PT/INR CROSSTABULATION
 
Content_ 
Bait 
Powder 
Paste 
Total 
 
Chi square = 8.438* p<0.05 S
60 patients had complaints.
0%
20%
40%
60%
80%
100%
120%
Abnormal
80 
PTINR 
Abnormal Normal
Count 31 9 
% within 
PT/INRr 34.4% 15.0%
Count 39 39
% withinPT/INR 43.3% 65.0%
Count 20 12
% within 
PT/INR 22.2% 20.0%
Count 90 60
% within 
PT/INR 100.0% 100.0%
 
 
 Paste and bait had complication
 
Normal
34%
15%
43%
65%
22%
20%
 
Total 
 
40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
s 
Paste
Powder
Bait
  
 
 
Content_ 
Bait 
Powder 
Paste 
withinbreathlessness
Total 
withinbreathlessness
Pearson Chi-Square 
Few people only had this complaints
0%
20%
40%
60%
80%
100%
Absent
29%
51%
20%
81 
BREATHLESSNESS 
CROSSTAB 
BREATHLESSNES
Absent Present
Count 40 0
% within 
breathlessness 28.6% 0.0%
Count 72 6
% within 
breathlessness 51.4% 60.0%
Count 28 4
% 
 
20.0% 40.0%
Count 140 10
% 
 
100.0% 100.0%
 
= 4.739 p= 0.094 N S 
, not much elevated.
present in powder form 
Present
0%
60%
40%
 Total 
 
 40 
 26.7% 
 78 
 52.0% 
 32 
 21.3% 
 150 
 100.0% 
 
 Percentage  
Paste
Powder
Bait
  
 
 
Content_ 
Bait 
% within leucopenia
Powder 
% within leucopenia
Paste 
% within leucopenia
Total 
% within leucopenia
Pearson Chi-Square 
5 patients had this complaints,
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Absent
27%
51%
22%
82 
CROSSTAB 
LEUKOPENIA
Absent Present
Count 39 
 26.9% 20.0%
Count 74 
 51.0% 80.0%
Count 32 
 22.1% 0.0%
Count 145 
 100.0% 100.0%
= 1.969  p= 0.374 N S 
 
 not much elevation , 
80% in powder form 
Present
20%
80%
0%
 
Total 
 
1 40 
 26.7% 
4 78 
 52.0% 
0 32 
 21.3% 
5 150 
 100.0% 
 
in that  
Paste
Powder
Bait
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CLINICAL AND BIOCHEMICAL CHART OF BAIT 
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CLINICAL AND BIOCHEMICAL CHART OF  
POWDER POISONING 
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CLINICAL AND BIOCHEMICAL CHART OF PASTE POISONING 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
 Rodenticide poisoning and its manifestation, clinically and 
biochemically. This study is based on different form of Rodenticide. The 
sample size are 150 patients. 
AGE:       Age classified as 20-40 years, 41-60 years and more than 60 years. 
                 In 20-40years  = 65.3% consumed. 
                  In 41-60years = 24%intake. 
                   In >61years  = 10.7% taken. 
 More number of poison consumed in the age group between 20 to 40 
years of age and mostly young people are involved in this. Young people are  
highly affected by the suicidal intention.(98 out of 150 patients) 
 Age group between 41 to 60 years are moderate in number (36 out of 
150) 
 Older age group are less in number, in consuming the poison (16 out of 
150 patients) 
 SEX : Female are mostly affected than male. In our study the poison 
intake are more in female .i.e 85 out of 150 patients are female and 65 out of 
150 patients are male. 
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               Female : 56.7% 
              Male  :  43.3%  
          This study shows that intention to attempt is more in female.          
DOSE:   
 5-30grams   :   78% 
 31-50 grams   : 13.3% 
 More than 50 grams : 8.7%  
It shows that out of 150 patients, 117 have consumed 5-30grams,  
20 have consumed 31-50 grams and 13 have consumed more than 50 grams. 
AMOUNT CONSUMED IN DIFFERENT FORMS 
 Bait form: People have consumed poison more in bait form (5-30 
grams) which is around 65%. Those who have consumed between 31-50 
grams is about 30% and those who have consumed more than 50 grams are 
very few which, is just 5%. 
 Powdered form: The intake in powdered form is about 89% (5-30 
grams), and those who have taken 31-50 grams comes to 6.4%, and those 
who have taken more than 50 grams has 3.8%. 
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 Paste form: Around 65.6% have consumed 5-30 grams in paste form, 
whereas 9.4% has taken between 31-50 grams and more than 50 grams comes 
to 25% of paste consumption. 
DURATION: 
 Time taken by the people to reach hospital: 4% of people reach 
hospital in less than 6 hours, 12% of people reach within 6-12 hours, 10% of 
people reach within 12-24 hours, 67.3% of people reach within 24-72 hours, 
3.3% of people reach within 3-7 days, and also 3.3% of people reach within 
7-14 days. 
DEATH 
 According to the study, out of 150 patients, 10 patients have died. 
From this 10 patients, 8 patients have died due to consumption in paste form 
and 2 patients have died due to the consumption in bait form. 
DOSAGE AFFECTING DEATH 
 Those who have taken more than 50 grams have high death rate(10 out 
of 150 patients) whereas those taken from 30-50 grams and 5-30 grams does 
not show any death rate. 
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 CLINICAL PROFILE 
VOMITING: Out of 150 patients, 90 of them suffer vomiting, in 
which 54 of them have taken in powdered form, 18 of them in bait form and 
again 18 of them in paste form. 
                     Powder : 60% 
  Paste    : 20% 
                     Bait  :     20% 
ABDOMINAL PAIN: 
                    Paste  : 6.7% 
                    Bait  : 6.7% 
                   Powder : 86.7%   
 Only 15 out of 150 patients have complained Abdominal pain, in 
which 13 patients have taken it in powdered form. 
HEMATEMESIS 
 40 out of 150 patients have bleeding manifestations in the form of 
blood vomiting. 24 persons from bait consumption, 14 from paste 
consumption and 2 people from powder intake. 
                     POWDER : 5% 
  
90 
 
                     BAIT    :   60% 
  PASTE  :  35% 
MALENA: 
 This condition occurs around 24 persons from bait consumption, 
14 from paste consumption and 2 people  from powder intake. 
  Paste  : 35% 
                   Bait  :    60% 
                  Powder : 5% 
ALTERED SENSORIUM:  
 Out of 150 patients, only 5 of them have Altered sensorium findings, in 
which 4 of them have taken in paste form and 1 of them in powdered form. 
This Altered sensorium occurs due to hepatic dysfuntion                    
                Powder : 20% 
               Paste  :  80% 
              Bait    :  0%.  
 Its due to hepatic dysfunction and hepatic encephalopathy main clinical 
manifestation in the study. 
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JAUNDICE: 
                     Paste  : 80% 
                     Bait   : 20% 
                    Powder : 0%  
 In 150 patients only 10 patients were presented with jaundice, in 
which, 8 from paste intake and 2 from bait intake.  
BILIRUBIN: 
  Paste  : 80% 
               Powder : 0% 
              Bait  : 20%  
  Those who have jaundice will have elevated Bilirubin level in blood. It 
is commonly seen in paste consumption. 
PT/INR:    
             Powder : 43.3% 
            Paste   : 22.2% 
           Bait  :  34.4%  
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 Totally 60 out of 150 patients have prolong bleeding time. Increase 
severity in all three forms of powder, paste and bait intake.    
HYPOKALEMIA: 
  Bait  : 20% 
  Powder : 76% 
   Paste  : 4%  
 Potassium value will become low in powder poisoning. Out of 25 
patients, 19 of them have decreased K + level in serum. 
LUNG INFILTRATION: 
 Very minimal amount of people get pulmonary edema. Here, powdered 
form involves major part in Lung Infilteration. 
 In powder 5% of people chest x-ray shows bilateral infiltration. 
ULTRA SOUND ABDOMEN: 
          Some people who consumed in powder form carries changes in ultra 
sound abdomen. Bait rate is 40% in cholecystitis, powder carries 60% and nil 
rate in paste form. 
 Out of 150 patients, 5 Patients suffer Fatty liver, in which 4 of them 
due to powder poisoning and 1 from paste intake. 
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CHEST PAIN AND BREATHLESSNESS: 
 Out of 150 patients, 10 suffer from chest pain and breathlessness, in 
which 6 of them has taken in powdered form and 4 of them in paste form. 
FEVER: 
 It is an insignificant clinical profile, more involved in powder form 
around 70%. 
HEMATURIA: 
 Out of 150 patients, 10 suffer from Hematuria, in which 7 of them has 
taken powdered form and 3 of them taken in bait form. 
GUMBLEED: 
 Gum bleeding involves 7 patients consumed in powdered form, 2 from 
bait and 1 from paste intake. 
SEIZURES: 
          Seizures occurs in 6 patients who took in powdered form. It is  a  rare 
presentation in our study. 
HEADACHE: 
 It also rare entity insignificant role in clinical manifestation. 
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WEAKNESS OF LIMBS: 
           Cases reported in powder form only in this study. 
OLIGURIA: 
          Minimal amount of patients who consumed powder, presented with 
decreased urine output. Out of 150 patients, 3 persons from powder, 2 
patients from paste suffer Oliguria. 
UREA AND CREATININE:  
 Urea more than a normal range in patients, 3 in powder followed by  
2 in paste. End results shows 5 patients out of 150. 
           2 persons from paste and 3 persons from bait shows Creatinine. 
ARRYTHMIA IN ECG: 
           10 patients show abnormal ECG in which 8 of them consumed powder  
and the remaining in  paste form. 
LYMPHOCYTOPENIA: 
 In 150 Patients, 5 patients clinical profile shows decreased white blood 
cells. Mostly seen in powdered form.  
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CONCLUSION 
1. In our study the most common Rodenticide consumed was rat killer 
powder, followed by paste and then by bait. 
2. The paste form of Rodenticide contributes to higher death rate when 
compared with other forms. 
3. Female consumption is higher than the male consumption. 
4. The Age group between 20-40 years have the most consumption of 
poison intake. 
5. The common complaint of poison intake is vomiting, out of which 
powdered form has the most percentage. 
6. Death occurs only when the patients have consumed more than 50 
grams. 
7. Most of the people reach hospital within 24-72 hours only. 
8. More people suffer bleeding tendency due to Bait consumption. 
9. More number of persons take lesser amount of poison around 5-30 
gram. 
10. More patients die due to the consumption in Paste form. 
11. Hepatic encephalopathy is caused due to high consumption in paste 
form. 
12. High intake in powder form leads to Hypokalemia. 
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13. N-acetyl cysteine plays a vital role in non liver transplant patients who 
consumed Rodenticide poison. 
14. In this study, haematemesis and melaena are the major symptoms in 
bait consumption. 
15. Jaundice and elevated liver parameters are the manifestations in paste 
consumption. 
 
 
 
 
 
 
  
  
 
 
SUMMARY 
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SUMMARY 
 Rodenticide is a most common poisoning in India. It is easily available 
due to its low cost. This study is based on the patients clinical and 
biochemical profile, with Rodenticide consumption in Madras Medical 
College, Chennai. The participants were briefly explained about this study 
and the procedures. Proper written consent was got from them. Before the 
study, the history of the patients were noted and relevant investigation was 
done. 
 The most common forms of Rodenticides available are Bait, Powder 
and Paste, where Powder form was consumed by most of the patients. But the 
study reveals that paste consumption has high death rate when taken above 
50 grams. Most people also suffer bleeding tendency due to Bait 
consumption. Hypokaelemia and Hepatic encephalopathy are also caused due 
to the intake of this Rodenticides. 
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ANNEXURES 
  
PROFORMA 
PATIENT DETAILS: 
Name:     Age:   Sex:   
 
IP No. : 
 
PRESENTING COMPLAINTS  
H/o fever 
H/o nausea/vomiting      
H/o hematemesis, 
H/O hematuria, 
H/o melaena, 
H/o gumbleed 
H/o any other bleeding manifestation 
H/o abdominal pain 
H/o abdominal distension 
H/o loose stools 
H/o chestpain 
H/o breathlessness 
H/o seizures,altered sensorium 
H/o weakness of limbs          
H/o intake of any drugs 
Co – Morbid Illness  : 
Significant Past History : 
 
CLINICAL EXAMINATION: 
Pulse :     BP : 
RR :      Temp : 
Pallor :     Icterus : 
CVS  :     RS : 
P/A : 
CNS: 
INVESTIGATIONS : 
Hemogram : 
Liver function Test:  
Renal Function Test : 
BT/CT/PT/INR : 
Stool occult blood 
Blood Grouping : 
ECG : 
CXR : 
USG Abdomen . 
ABBREVATION 
 
ARDS - Acute Respiratory Distress Syndrome 
BT   -  Bleeding Time 
BP  - Blood pressure 
CBC   -  Complete Blood Count 
Ct   -  Clotting time 
CT   -  Computed Tomography 
CXR  - Chest x ray 
ECG  - Electrocardiogram 
HB   -  Haemoglobin 
HE   -  Hepatic Encephalopathy 
INR   -  International normalized ratio 
LFT   -  Liver Function Test 
Na    - Sodium 
PT  -  Prothrombin Time 
RFT   -  Renal Function Test 
SGOT - serum glutamic oxaloacetic transaminase 
SGPT  -  serum glutamic pyruvic  transaminase 
TC   -  Total count  
USG   -  Ultrasonogram 
  
INFORMATION SHEET 
 We are conducting a study on “A STUDY ON THE CLINICAL 
AND BIOCHEMICAL PROFILE OF PATIENTS ADMITTED IN 
TOXICOLOGY WARD WITH RODENTICIDE POISONING” among 
patients attending Rajiv Gandhi Government General Hospital, Chennai and for 
that your specimen may be valuable to us. 
The purpose of this study is  
1. Clinical and biochemical profile of patients with rodenticide ingestion. 
We are selecting certain cases and if you are found eligible, we may be 
using your information which in any way do not affect your final report or 
management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of the Investigator   Signature of Participant 
 
Date: 
Place: 
  
PATIENT CONSENT FORM 
Study Detail : “A STUDY ON THE CLINICAL AND 
BIOCHEMICAL PROFILE OF PATIENTS 
ADMITTED IN TOXICOLOGY WARD WITH 
RODENTICIDE POISONING” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. ❏ 
 
Signature/thumb impression 
 
Patient’s Name and Address: 
Signature of Investigator 
Study Investigator’s Name : 
Dr.SHOBANA.D, 
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SNO AGE SEX IP NO Content 
DURATION 
IN
DEATH DOSE FEVER 
VOMI
TING 
HEMATE
MESIS
MELENA HEMATURIA GUMBLEED
ABDOMINAL 
PAIN
ABDOMINAL 
DISTENSION
CHEST 
PAIN
BREATHL
ESNESS
SEIZURES 
ALTERED 
SENSORIUM
HEADACHE
WEEKNESS 
OF LIMBS 
1 20 F 59870 PASTE 6- 12 HRS - 15 g + - - - - - - - + + + + - -
2 34 M 39584 POWDER 6- 12 HRS - 10 g - + - - - - + - - - - - - -
3 45 F 59876 BAIT 12-24 HRS - 30 g - - + + + - - - - - - - - -
4 28 M 39592 POWDER 6- 12 HRS - 15 g - + - - - - - - - - - - - -
5 20 F 59882 POWDER 6- 12 HRS - 10 g - + - - - + - - - - - - - -
6 54 F 39600 BAIT 24-72 HRS - 50 g - - + + - - - - - - - - + -
7 34 M 59888 POWDER 6- 12 HRS - 15 g + + - - - - - - - - - - - -
8 39 M 39608 POWDER 6- 12 HRS - 10 g - - - - - - - - - - - - - -
9 53 F 59894 BAIT 12-24 HRS - 40 g - + + + - - - - - - - - - -
10 20 F 39616 POWDER 6- 12 HRS - 15 g + + - - - + - - - - - - - -
11 37 F 59900 POWDER 6- 12 HRS - 10 g - - - - - - + - + + + - + -
12 34 F 39624 POWDER 6- 12 HRS - 40 g - + - - + - - - - - - - - -
13 54 M 59906 BAIT 12-24 HRS - 30 g - - + + - - - - - - - - - -
14 48 F 39632 POWDER 6- 12 HRS - 15 g - + - - - - - - - - - - - -
15 20 M 59912 POWDER 0-6 HRS - 10 g - + - - - - - - - - - - - -
16 24 M 39640 BAIT 12-24 HRS - 40 g - + + + - + - - - - - - - -
17 22 F 59918 POWDER 0-6 HRS - 15 g + + - - - - - - - - - - - -
18 34 F 39648 BAIT 24-72 HRS - 40 g - - + + - - - - - - - - - -
19 35 M 59924 POWDER 0-6 HRS - 10 g + + - - - - - - - - - - - -
20 20 F 39656 POWDER 0-6 HRS - 15 g - - - - - - - - - - - - - -
21 33 F 59930 POWDER 0-6 HRS - 10 g - + - - - + - - - - - - - -
22 48 F 39664 POWDER 0-6 HRS - 15 g - + - - - - - - - - - - - -
23 54 F 59936 BAIT 12-24 HRS - 30 g + - + + - - - - - - - - - -
24 39 F 39672 POWDER 12-24 HRS - 10 g - + - - - - + - - - - - - -
25 20 M 59942 POWDER 12-24 HRS - 55 g - + - - + - - - - - - - + -
26 22 F 39680 PASTE 12-24 HRS - 15 g - - - - - - - - + + + + - -
27 32 F 59948 POWDER 12-24 HRS - 10 g - + - - - - - - - - - - - -
28 24 M 39688 BAIT 3-7 Days - 40 g - + + + - - - - - - - - - -
29 28 M 59954 POWDER 12-24 HRS - 15 g + - - - - - - - - - - - - -
30 20 F 39696 POWDER 12-24 HRS - 10 g + + - - - - - - - - - - - -
31 39 F 59960 POWDER 12-24 HRS - 15 g - + - - - - - - - - - - - -
32 48 M 39704 BAIT 3-7 Days - 30 g - + + + + - - - - - - - - -
33 54 F 59966 POWDER 12-24 HRS - 10 g - - - - - + - - - - - - - -
34 26 F 39712 POWDER 12-24 HRS - 15 g - + - - - - - - - - - - - -
35 50 M 59972 POWDER 12-24 HRS - 10 g - + - - - - - - - - - - + -
36 34 F 39720 PASTE 6-12 HRS DEATH 60 g - - + + - - - - - - - - - -
37 22 M 59966 POWDER 24-72 HRS - 15 g - + - - - - + - - - - - - -
38 33 M 39728 POWDER 24-72 HRS - 10 g - + - - - + - - - - - - - -
39 32 F 59984 BAIT 3-7 Days - 40 g - - + + - - - - - - - - - -
40 54 F 39736 POWDER 24-72 HRS - 5 g - + - - - - - - + + + - - -
41 48 F 59990 POWDER 24-72 HRS - 15 g - - - - - - - - - - - - - +
42 53 F 39744 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
JAUNDICE OLIGURIA BP HB TC PLATELETS URIEA CRATININE SODIUM POTASIUM CALCIUM BILLIRUBIN BT/CT PT/INR SGOT/SGPT
STOOL 
OCCULTBLOOD
ARRTHYMIA 
IN ECG
ULTRASOUND 
ABDOMEN
LUNG ILFILTERATION 
IN CHEST X-RAY
CT BRAIN 
- + INC 14.5 12000 207000 150 4.8 120 3.4 15 0.9 2/4 12/1.2 20/35 - - NORMALSTUDY - NORMAL
- - - 14 8000 250000 25 0.9 136 3.7 11.5 1.1 5/6 11/0.9 35/20 - + NORMALSTUDY - -
- - - 6 11,500 30,000 30 0.8 138 3.4 10.5 1 9/10 40/4.5 20/35 + - NORMALSTUDY - -
- - - 13.8 9000 207000 20 0.9 136 3.8 11.5 0.9 2/4 12/1.2 15/20 - - NORMALSTUDY - -
- - - 12.9 9200 300000 25 1 140 3.4 11.5 1 2/6 12/0.8 35/20 - - NORMALSTUDY - -
+ - - 13.5 11000 20,000 35 1 136 3.7 10 4.5 12/10 35/3 110/120 + - NORMALSTUDY - ICH
- - - 14 9000 207000 25 0.9 138 3.4 11.5 1.1 2/4 12/1.2 20/35 - - CHOLECYSTITIS - -
- - - 13.2 9200 207000 30 0.8 136 3.9 10.5 0.9 5/6 11/0.9 25/15 - - NORMALSTUDY - -
- - DEC 12 12000 30,000 20 0.9 142 3.4 11.5 1 9/10 40/4.5 35/20 + - NORMALSTUDY - -
- - - 14.5 9000 300000 25 1 136 3.8 10 0.9 2/4 12/1.2 20/35 - + NORMALSTUDY + -
- - - 14 9200 207000 40 0.9 148 3.4 10 1 2/6 10/1 15/20 - - NORMALSTUDY - NORMAL
- - - 13.8 9000 250000 30 0.9 138 3.7 11.5 0.9 2/6 12/1.2 20/35 - - NORMALSTUDY - -
- - - 8 11,500 60,000 25 0.8 136 3.4 10.5 1.1 15/12 50/5 28/30 + - NORMALSTUDY - -
- - - 12.9 9200 207000 29 0.9 140 4 11.5 0.9 2/4 11/0.9 20/35 - - NORMALSTUDY - -
- - - 14 8500 300000 25 1 136 3.4 10 1 5/6 12/1.2 20/35 - - NORMALSTUDY - -
- - - 13.9 11,500 30,000 20 0.9 145 4.2 11.5 0.9 16/12 35/3 35/20 + - NORMALSTUDY - -
- - - 14.5 9000 207000 25 0.8 136 3.4 10.5 1.1 2/4 12/0.8 15/20 - + NORMALSTUDY - -
+ - DEC 7.2 12000 90,000 30 0.9 138 3.8 11.5 5.5 12/10 40/4.5 90/85 + - NORMALSTUDY - -
- - - 14 8500 300000 29 1 136 3.4 10.4 0.9 3/5 12/1.2 35/20 - - NORMALSTUDY - -
- - - 13.8 9000 207000 25 0.9 140 3.7 11.5 1 2/6 11/0.9 35/20 - - FATTY LIVER + -
- - - 12.9 9000 250000 30 0.9 136 3.4 10.5 0.9 2/4 12/1.2 20/35 - - NORMALSTUDY - -
- - - 14 9000 207000 25 0.8 138 3.9 11.5 1.1 5/6 10/1 25/15 - + CHOLECYSTITIS - -
- - - 13.5 12000 30,000 20 1 136 3.4 9.5 0.9 9/10 50/5 20/35 + - NORMALSTUDY - -
- - - 14.5 8500 300000 30 0.9 142 3.8 11.5 1.1 2/4 12/1.2 35/20 - - NORMALSTUDY - -
- - - 14.2 8500 207000 25 0.8 136 3.4 10.5 0.9 3/5 11/0.9 15/20 - - NORMALSTUDY - -
- + - 13.8 11,500 300000 110 5 110 3.7 10.2 1 2/4 12/1.2 20/35 - - NORMALSTUDY - NORMAL
- - - 14 9200 207000 35 0.9 138 3.4 11.5 0.9 2/6 12/0.8 28/30 - - NORMALSTUDY + -
- - - 12.5 12000 20,000 25 1 136 4 10 1.1 20/15 40/4.5 35/20 + - NORMALSTUDY - NORMAL
- - - 12.9 8500 300000 30 0.9 138 3.9 11.5 0.9 2/4 12/1.2 15/20 - - NORMALSTUDY - -
- - - 14.5 9000 207000 25 0.8 136 3.7 10.5 1 5/6 11/0.9 20/35 - - NORMALSTUDY - -
- - - 13.2 11000 250000 20 0.9 138 3.8 11.5 0.9 2/4 12/1.2 35/20 - + FATTY LIVER - -
- - - 7 12000 30,000 25 1 136 3.4 10 1.1 15/12 50/5 25/15 + - NORMALSTUDY - -
- - - 14.5 11,500 207000 25 0.8 140 4.4 11.5 1 3/5 10/1 35/20 - - NORMALSTUDY - -
- - - 14 11000 300000 30 1 136 3.7 10.5 0.9 2/4 12/1.2 15/20 - - NORMALSTUDY + -
- - - 13.8 11,500 207000 25 0.8 145 3.4 11.5 1.1 2/6 12/0.8 20/35 - - NORMALSTUDY - -
+ - - 12.9 12000 200700 29 1 136 3.8 10 4.5 2/4 12/1.2 110/120 + - NORMALSTUDY - -
- - - 13.9 11000 300000 25 0.8 140 3.4 11.5 0.9 5/6 11/0.9 35/20 - - NORMALSTUDY - -
- - - 14.5 11,500 207000 30 0.9 136 4 10.5 1 2/4 12/1.2 28/30 - - NORMALSTUDY - -
- - - 13.5 12000 30,000 20 1 138 3.7 9.5 1.1 9/10 40/4.5 35/20 + - NORMALSTUDY - -
- - INC 13.8 11000 250000 35 0.8 150 3.4 15.5 0.9 3/5 10/1 15/20 - - NORMALSTUDY - NORMAL
- - - 12.9 2000 207000 30 1 136 2 11.5 1 2/4 12/1.2 20/35 - - NORMALSTUDY - -
- - - 14.5 12000 300000 35 0.9 142 3.7 10.5 0.9 2/6 11/0.9 35/20 - + CHOLECYSTITIS - -
43 39 M 59996 BAIT 3-7 Days - 30 g + - + + + - - - - - - - - -
44 35 M 39752 POWDER 24-72 HRS - 5 g - + - - - + - - - - - - - -
45 34 F 60002 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
46 53 M 39760 POWDER 24-72 HRS - 5 g - + - - - - + - - - - - - -
47 48 M 60008 PASTE 6-12 HRS DEATH  80 g - - + + - - - - - - - - - -
48 25 F 39768 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
49 37 M 60014 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
50 39 F 39776 POWDER 24-72 HRS - 40 g - + - - + - - - - - - - + -
51 54 F 60020 BAIT 3-7 Days DEATH 90 g - - + + - - - - - - - - - -
52 28 M 39784 POWDER 24-72 HRS - 5 g + + - - - - - - - - - - - -
53 34 F 60026 POWDER 24-72 HRS - 15 g - + - - - - + - + + + - - -
54 53 M 39792 PASTE 6-12 HRS DEATH 60 g - - + + - + - - - - - - - -
55 39 M 60032 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
56 62 F 39800 POWDER 24-72 HRS - 55 g - + - - + - - - - - - - - -
57 29 F 60038 POWDER 24-72 HRS - 15 g - - - - - - - - - - - - - -
58 24 M 39808 BAIT 7-14 Days - 40 g - + + + - - + - - - - - - -
59 39 F 60044 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
60 62 F 39816 POWDER 24-72 HRS - 5 g - - - - - - + - - - - - - -
61 28 M 60050 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
62 54 F 39824 BAIT 7-14 Days - 30 g - + + + - - - - - - - - - -
63 48 F 60056 POWDER 24-72 HRS - 40 g - + - - + - - - - - - - - -
64 53 M 39832 POWDER 24-72 HRS - 15 g - - - - - - + - - - - - - -
65 26 F 60062 BAIT 7-14 Days - 40 g - + + + - + - - - - - - - -
66 37 M 39840 POWDER 24-72 HRS - 5 g - + - - - - - - + + + - - -
67 22 M 60068 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
68 48 F 39848 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
69 54 M 60074 BAIT 7-14 Days - 30 g - + + + - - - - - - - - - -
70 67 M 39856 POWDER 24-72 HRS - 15 g - + - - - - + - - - - - - -
71 62 F 60080 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
72 28 M 39864 PASTE 24-72 HRS - 15 g - + - - - - - - + + + + - -
73 31 F 60086 BAIT 7-14 Days - 40 g - - + + - - - - - - - - - -
74 33 F 39872 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
75 37 M 60092 POWDER 24-72 HRS - 55 g - + - - + - + - - - - - - -
76 50 M 39880 POWDER 24-72 HRS - 5 g - + - - - + - - - - - - - -
77 48 F 60098 PASTE 6-12 HRS DEATH  80 g - + + + - - - - - - - - - -
78 29 F 39888 POWDER 24-72 HRS - 15 g - - - - - - - - - - - - - +
79 31 M 60104 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
80 35 F 39896 POWDER 24-72 HRS - 15 g - + - - - - - - + + + - - -
81 28 M 60110 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
82 62 M 39904 BAIT 24-72 HRS - 30 g - - + + - - - - - - - - - -
83 22 F 60116 POWDER 24-72 HRS - 5 g - + - - - - + - - - - - - -
84 53 M 39912 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
85 67 M 60122 PASTE 24-72 HRS - 5 g - + - - - - - - + + + + - -
86 32 F 39920 BAIT 24-72 HRS DEATH 80 g - + + + - - - - - - - - - -
87 33 F 60128 POWDER 24-72 HRS - 15 g - - - - - - - - - - - - - -
- - DEC 8.3 11,500 200700 30 0.8 136 3.9 10 1.1 5/6 12/1.2 25/15 + - NORMALSTUDY - -
- - - 13.1 11000 207000 25 1 138 3.4 11.5 1 2/4 12/0.8 35/20 - - NORMALSTUDY - -
- - - 13.8 12000 300000 30 1 136 3.7 10.5 1.1 3/5 10/1 20/35 - - NORMALSTUDY - -
- - - 14.5 11,500 207000 20 0.9 140 3.4 11.5 0.9 2/6 11/0.9 15/20 - - NORMALSTUDY - -
+ - - 5 12000 30,000 25 0.8 136 4.2 10.4 4.9 12/10 35/3 90/85 + - NORMALSTUDY - -
- - - 12.9 11000 300000 30 1 145 3.8 11.5 1 2/4 12/1.2 28/30 - - NORMALSTUDY - -
- - - 13.8 12000 207000 30 0.9 136 3.7 10.5 1.1 5/6 12/0.8 35/20 - - NORMALSTUDY - -
- - - 13.2 11,500 300000 25 1 140 3.9 11.5 0.9 2/4 11/0.9 20/35 - + FATTY LIVER + -
- - - 13.5 12000 20,000 30 0.8 136 4 10 1.1 15/10 40/4.5 15/20 + - NORMALSTUDY - ICH
- - - 14.5 11000 207000 29 0.9 138 3.8 11.5 1.1 3/5 10/1 35/20 - - NORMALSTUDY - -
- - - 13.8 12000 300000 25 0.9 155 3.7 10.4 0.9 2/6 12/1.2 25/15 - - NORMALSTUDY - NORMAL
+ - - 12.9 11,500 30,000 25 1 136 4.4 10.5 5.5 9/10 50/5 120/100 + - NORMALSTUDY - -
- - - 14.5 12000 207000 20 0.9 142 3.9 11.5 1 2/4 11/0.9 20/35 - - NORMALSTUDY - -
- - - 13.9 12000 207000 29 1 145 3.7 10 1 5/6 12/0.8 35/20 - - NORMALSTUDY - -
- - - 13.8 12000 250000 25 0.8 136 3.8 11.5 0.9 2/4 12/1.2 15/20 - - NORMALSTUDY - -
- - - 7.5 11000 60,000 25 0.9 138 4 10.5 1 20/15 40/4.5 20/35 + - NORMALSTUDY - -
- - - 12.9 12000 207000 30 1 140 3.7 11.5 0.9 3/5 10/1 35/20 - + NORMALSTUDY - -
- - - 13.2 12000 300000 25 0.9 136 4.2 9.5 0.9 2/4 11/0.9 20/35 - - NORMALSTUDY - -
- - - 14.5 11,500 207000 35 1 138 3.8 11.5 1.1 5/6 12/1.2 35/20 - - NORMALSTUDY - -
- - - 12.5 11000 30,000 20 0.9 136 3.7 10.5 0.9 12/10 50/5 20/35 + - NORMALSTUDY - -
- - - 12.6 12000 300000 25 0.8 142 3.9 10 0.9 2/4 12/0.8 28/30 - - FATTY LIVER - -
- - - 12.9 12000 207000 29 1 136 4 10.5 1 2/6 12/1.2 20/35 - - NORMALSTUDY - -
- - DEC 14 11000 90,000 25 0.9 145 3.7 11.5 1.1 15/12 40/4.5 35/20 + - NORMALSTUDY - -
- + - 14.5 11,500 300000 95 3.8 152 3.8 11 0.9 2/4 10/1 20/35 - - NORMALSTUDY - NORMAL
- - - 13.9 11000 300000 20 1 136 3.6 10 1.1 5/6 12/1.2 25/15 - - NORMALSTUDY - -
- - - 12.9 12000 207000 25 0.9 138 3.7 10.4 1 2/4 11/0.9 20/35 - - NORMALSTUDY - -
- - - 6 11,500 30,000 30 0.8 140 3.8 11.5 1.1 16/12 35/3 35/20 + - NORMALSTUDY - -
- - - 14.2 12000 250000 25 0.9 142 3.8 10.5 0.9 3/5 12/1.2 20/35 - - NORMALSTUDY - -
- - - 14.5 11000 300000 29 1 138 3.7 10 1 2/4 10/1 15/20 - - NORMALSTUDY - -
- - INC 13.2 12000 207000 23 0.8 120 3.9 17 0.9 5/6 12/1.2 20/35 - - NORMALSTUDY - NORMAL
- - - 12.5 12000 20,000 25 0.9 140 3.7 10 1.1 15/10 40/4.5 35/20 + - NORMALSTUDY - NORMAL
- - - 12.9 12000 300000 20 0.8 145 4 10.5 1 2/6 11/0.9 28/30 - - NORMALSTUDY - -
- - - 14.5 11,500 207000 25 1 138 3.8 9.5 0.9 2/4 12/0.8 20/35 - - NORMALSTUDY - -
- - - 13.9 11000 300000 35 1 142 3.7 10.5 1 5/6 12/1.2 35/20 - - NORMALSTUDY - -
+ - - 12.9 12000 200700 25 0.9 140 4 10 4.5 2/4 11/0.9 110/120 + - NORMALSTUDY - -
- - - 14.5 3000 207000 30 0.8 142 2.3 10 0.9 2/6 12/1.2 20/35 - - NORMALSTUDY - -
- - - 14.4 12000 300000 25 1 138 3.8 10.5 1.1 5/6 10/1 35/20 - - NORMALSTUDY - -
- + - 14.5 12000 207000 140 5 149 3.9 11.5 0.9 2/4 11/0.9 20/35 - - NORMALSTUDY - NORMAL
- - - 14.2 12000 300000 20 0.9 140 4.2 9.5 1 3/5 12/1.2 15/20 - - NORMALSTUDY - -
- - - 8 11000 200700 25 0.8 142 4 10.5 0.9 2/4 12/0.8 20/35 + - NORMALSTUDY - -
- - - 13.1 11,500 207000 29 0.9 138 3.9 10 1.1 5/6 12/1.2 25/15 - - NORMALSTUDY - -
- - - 14.5 12000 300000 25 1 140 4.4 10.5 0.9 2/6 11/0.9 20/35 - - NORMALSTUDY - -
- - INC 12.9 11000 207000 32 0.7 115 3.8 10 1 2/4 12/1.2 15/20 - - NORMALSTUDY - NORMAL
- - - 6.5 11000 20,000 30 0.9 138 3.9 10 0.9 12/10 50/5 35/20 + - NORMALSTUDY - ICH
- - - 13.9 12000 300000 25 0.9 145 4 10.5 1.1 5/6 10/1 20/35 - - NORMALSTUDY - -
88 53 M 39928 POWDER 24-72 HRS - 5 g - - - - - - + - - - - - - -
89 26 F 60134 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
90 25 M 39936 BAIT 24-72 HRS - 40 g - + + + - - - - - - - - - -
91 62 F 60140 POWDER 24-72 HRS - 40 g - - - - + - - - - - - - - -
92 26 M 39944 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
93 29 F 60146 BAIT 24-72 HRS - 30 g - - + + - - - - - - - - - -
94 37 M 39952 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
95 67 F 60152 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
96 28 M 39960 PASTE 6-12 HRS DEATH 70 g - - + + - - - - - - - - - -
97 22 F 60158 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
98 29 M 39968 POWDER 24-72 HRS - 15 g - + - - - - - - - - - - - -
99 24 F 60164 BAIT 24-72 HRS - 40 g - - + + - - - - - - - - - -
100 37 F 39976 POWDER 24-72 HRS - 5 g - + - - - - - - + + + + - -
101 50 M 60170 POWDER 24-72 HRS - 15 g - - - - - - + - - - - - - -
102 31 F 39984 BAIT 24-72 HRS - 30 g - + + + - - - - - - - - - -
103 62 M 60176 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - +
104 33 F 39992 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - -
105 35 F 60182 PASTE 6-12 HRS DEATH 60 g - - + + - - - - - - - - - -
106 45 F 40000 BAIT 24-72 HRS - 15 g - + - - - - - - - - - - - -
107 67 M 60188 BAIT 24-72 HRS - 40 g - - + + - - - - - - - - - -
108 31 F 40008 PASTE 24-72 HRS - 5 g - + - - - - - - - - - - - -
109 29 F 60194 BAIT 24-72 HRS - 5 g - - - - - - - - - - - - - -
110 28 M 40016 PASTE 24-72 HRS - 15 g - - - - - - - - - - - - - -
111 50 M 60200 POWDER 24-72 HRS - 30 g - + + + - - - - - - - - - -
112 37 F 40024 POWDER 24-72 HRS - 40 g - + + + - - - - - - - - - -
113 26 F 60206 BAIT 24-72 HRS - 5 g - - - - - - - - - - - - - -
114 29 M 40032 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - +
115 37 F 60212 PASTE 24-72 HRS - 15 g - + - - - - - - - - - - - -
116 45 F 40040 BAIT 24-72 HRS - 5 g - - - - - - - - - - - - - -
117 67 M 60218 PASTE 24-72 HRS - 30 g - + + + - - - - - - - - - -
118 62 M 40048 POWDER 24-72 HRS - 5 g - + - - - - - - - - - - - -
119 32 F 60224 PASTE 24-72 HRS - 15 g - - - - - - - - - - - - - -
120 22 M 40056 BAIT 24-72 HRS - 5 g - + - - - - - - - - - - - -
121 62 F 60230 PASTE 6-12 HRS DEATH 70 g - + + + - - - - - - - - - -
122 24 F 40064 PASTE 24-72 HRS - 40 g - - + + - - - - - - - - - -
123 45 M 60236 PASTE 24-72 HRS - 15 g - + - - - - + - - - - - - -
124 25 F 40072 BAIT 24-72 HRS - 5 g - - - - - - - - - - - - - -
125 29 M 60242 PASTE 24-72 HRS - 15 g - - - - - - - - - - - - - -
126 31 M 40080 PASTE 24-72 HRS - 30 g - + + + - - - - - - - - - -
127 26 F 60248 BAIT 24-72 HRS - 5 g - + - - - - - - - - - - - -
128 29 M 40088 PASTE 24-72 HRS - 40 g - - + + - - - - - - - - - -
129 24 F 60254 PASTE 24-72 HRS - 30 g - + + + - - - - - - - - - -
130 45 M 40096 POWDER 24-72 HRS - 15 g - - - - - - - - - - - - - -
131 32 F 60260 POWDER 24-72 HRS - 5 g - - - - - - - - - - - - - +
132 67 M 40104 PASTE 24-72 HRS - 5 g - + - - - - - - - - - - - -
- - - 14.5 11,500 207000 35 1 138 3.9 10.4 0.9 3/5 11/0.9 28/30 - - NORMALSTUDY - -
- - - 12.9 11,500 250000 25 0.8 138 3.8 10.5 1 5/6 12/0.8 15/20 - - NORMALSTUDY - -
- - DEC 13.5 11000 90,000 20 0.9 142 4.2 10 0.9 20/15 40/4.5 25/15 + - NORMALSTUDY - -
- - - 12.6 12000 300000 25 1 138 3.9 10.5 1.1 2/6 11/0.9 15/20 - - NORMALSTUDY - -
- - - 14.5 12000 207000 30 0.9 138 3.8 10 0.9 5/6 10/1 28/30 - - NORMALSTUDY - -
- - - 8.5 11,500 200700 25 0.8 140 4 10.5 1 2/6 11/0.9 35/20 + - NORMALSTUDY - -
- - - 12.9 11000 300000 29 1 145 3.8 9.5 0.9 5/6 12/0.8 15/20 - - NORMALSTUDY - -
- - - 13.2 12000 207000 20 1 138 4 10.5 1.1 3/5 10/1 35/20 - - NORMALSTUDY - -
+ - - 12.9 11,500 60,000 25 0.9 142 3.8 9.5 6 15/12 35/3 90/85 + - NORMALSTUDY - -
- - - 14.2 12000 300000 35 0.8 138 3.9 10.5 0.9 5/6 11/0.9 25/15 - - NORMALSTUDY - -
- - - 13.9 11000 207000 25 0.9 140 4.4 10 1 2/6 12/0.8 35/20 - - NORMALSTUDY - -
- - - 7.5 12000 90,000 20 1 142 3.9 10.4 0.9 15/10 35/3 15/20 + - NORMALSTUDY - -
- + INC 14.4 11,500 300000 120 5.5 100 4 10.5 1.1 5/6 11/0.9 28/30 - - NORMALSTUDY - NORMAL
- - - 12.9 12000 300000 25 0.9 145 4.2 10.5 1 3/5 10/1 35/20 - - NORMALSTUDY - -
- - - 5.5 11000 200700 29 0.9 138 3.9 10 0.9 2/6 11/0.9 15/20 + - NORMALSTUDY - -
- - - 12.6 2300 207000 25 1 140 2.2 10.5 1.1 5/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 13.9 12000 250000 20 0.8 142 4.4 9.5 0.9 3/5 11/0.9 15/20 - - NORMALSTUDY - -
+ - - 14 11,500 90,000 25 0.8 138 3.9 10.5 4.5 16/12 50/5 120/100 + - NORMALSTUDY - -
- - - 14.2 11000 207000 35 0.9 142 4 10 1 5/6 10/1 35/20 - - NORMALSTUDY - -
- - - 12.5 12000 90,000 25 1 142 3.9 10.5 0.9 15/10 50/5 25/15 + - NORMALSTUDY - -
- - - 12.9 11,500 300000 29 0.8 138 4.2 10.4 1.1 2/6 11/0.9 15/20 - - NORMALSTUDY - -
- - - 13.1 11000 207000 20 1 140 3.9 10.5 0.9 5/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 13.2 12000 300000 25 0.9 145 3.9 10 1 3/5 11/0.9 15/20 - - NORMALSTUDY - -
- - - 12.9 11000 200700 29 1 138 4 10.5 0.9 5/6 10/1 28/30 + - NORMALSTUDY - -
- - - 6.5 12000 60,000 35 0.8 142 4.4 9.5 1.1 20/15 35/3 15/20 + - NORMALSTUDY - -
- - - 13.9 11,500 300000 25 0.8 140 4 10.5 0.9 3/5 11/0.9 25/15 - - NORMALSTUDY - -
- - - 13.2 3000 207000 20 0.8 138 2.7 9.5 1 5/6 12/0.8 15/20 - - NORMALSTUDY - -
- - - 12.6 12000 300000 25 0.8 142 4.2 10.5 0.9 3/5 11/0.9 25/15 - - NORMALSTUDY - -
- - - 12.9 11,500 207000 25 1 140 4 10 1.1 5/6 10/1 15/20 - - NORMALSTUDY - -
- - - 14 11000 90,000 29 0.8 145 4.4 10.5 0.9 16/12 50/5 25/15 + - NORMALSTUDY - -
- - - 13.2 11,500 300000 25 0.8 140 4 9.5 1 2/6 11/0.9 15/20 - - NORMALSTUDY - -
- - - 14.2 11000 250000 35 1 142 4 10.5 0.9 5/6 12/0.8 28/30 - - NORMALSTUDY - -
- - - 13.9 11,500 300000 25 0.8 142 4.2 10 1.1 3/5 11/0.9 15/20 - - NORMALSTUDY - -
+ - - 13.5 11000 200700 20 1 140 4.4 10.5 6 2/6 10/1 90/85 + - NORMALSTUDY - -
- - - 14.4 11,500 90,000 25 0.8 142 4.2 10.4 1 15/12 35/3 25/15 + - NORMALSTUDY - -
- - - 12.6 11000 207000 29 1 140 4.4 10.5 1.1 3/5 12/0.8 15/20 - - NORMALSTUDY - -
- - - 13.9 11,500 300000 29 0.8 142 4.2 9.5 1 5/6 10/1 25/15 - - NORMALSTUDY - -
- - - 14.4 11000 300000 20 0.8 140 4 10 1.1 2/6 12/0.8 15/20 - - NORMALSTUDY - -
- - - 9 11000 90,000 35 1 145 4.2 10.4 1 15/10 35/3 25/15 + - NORMALSTUDY - -
- - - 14.2 11,500 207000 29 0.8 140 4.4 10 1.1 3/5 10/1 15/20 - - NORMALSTUDY - -
- - - 14 11000 60,000 35 0.8 145 4.2 9.5 1 20/15 50/5 28/30 + - NORMALSTUDY - -
- - - 13.2 11,500 200700 29 0.8 140 4.4 10.4 1.1 5/6 12/0.8 15/20 + - NORMALSTUDY - -
- - - 13.9 11000 300000 35 1 142 3.6 10 1 2/6 10/1 25/15 - - NORMALSTUDY - -
- - - 13.1 2,900 207000 29 0.8 140 2.1 9.5 1.1 3/5 12/0.8 28/30 - - NORMALSTUDY - -
- - - 13.2 11000 300000 29 0.8 145 4.4 10.4 1 2/6 10/1 25/15 - - NORMALSTUDY - -
133 35 F 60266 BAIT 24-72 HRS - 15 g - + - - - - - - - - - - - -
134 24 F 40112 BAIT 24-72 HRS - 20 g - - - - - - - - - - - - - -
135 50 M 60272 PASTE 24-72 HRS - 15 g - + - - - - - - - - - - - -
136 31 F 40120 PASTE 6-12 HRS DEATH 60 g - + + + - - - - - - - - - -
137 45 M 60278 BAIT 24-72 HRS - 20 g - - - - - - - - - - - - - -
138 35 F 40128 PASTE 24-72 HRS - 15 g - + - - - - - - - - - - - -
139 33 M 60284 PASTE 24-72 HRS - 20 g - + - - - - - - - - - - - -
140 32 F 40136 BAIT 24-72 HRS - 15 g - - - - - - - - - - - - - -
141 67 F 60290 PASTE 24-72 HRS - 15 g - + - - - - - - - - - - - -
142 26 M 40144 BAIT 24-72 HRS - 20 g - - - - - - - - - - - - - -
143 24 F 60296 PASTE 24-72 HRS - 40 g - - + + - - - - - - - - - -
144 25 M 40152 BAIT 24-72 HRS - 15 g - + - - - - - - - - - - - -
145 45 F 60302 PASTE 24-72 HRS - 20 g - + - - - - - - - - - - - -
146 50 F 40160 BAIT 24-72 HRS - 20 g - + - - - - - - - - - - - -
147 35 F 60308 PASTE 24-72 HRS - 15 g - - - - - - - - - - - - - -
148 33 F 40168 PASTE 24-72 HRS - 20 g - + - - - - - - - - - - - -
149 32 M 60314 BAIT 24-72 HRS - 20 g - + - - - - - - - - - - - -
150 67 F 40176 BAIT 24-72 HRS - 15 g - - - - - - - - - - - - - -
- - - 12.6 11,500 207000 35 0.8 142 3.6 10 1.1 3/5 12/0.8 25/15 - - CHOLECYSTITIS - -
- - - 13.9 11000 300000 29 1 145 4.4 9.5 1.1 3/5 10/1 25/15 - - NORMALSTUDY - -
- - - 13.2 11,500 207000 29 0.8 140 4.4 9.5 1 2/6 12/0.8 28/30 - - NORMALSTUDY - -
+ - - 13.5 11000 90,000 35 0.8 142 4.2 10 4.5 16/12 35/3 90/85 + - NORMALSTUDY - -
- - - 14.2 11,500 300000 29 1 140 4.4 9.5 1 3/5 10/1 28/30 - - NORMALSTUDY - -
- - - 13.1 11000 207000 35 0.8 142 4.4 9.5 1 2/6 12/0.8 25/15 - + FATTY LIVER - -
- - - 13.2 11,500 300000 29 1 140 4.2 9.5 1 3/5 10/1 28/30 - - NORMALSTUDY - -
- - - 13.9 11000 207000 35 0.8 142 4.4 9.5 1 2/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 13.2 11,500 300000 29 1 140 4.2 9.5 1 3/5 10/1 25/15 - - NORMALSTUDY - -
- - - 12.6 11000 207000 35 1 142 3.6 9.5 1.1 2/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 14 11,500 200700 29 0.8 145 4.4 9.5 1 3/5 10/1 28/30 + - NORMALSTUDY - -
- - - 13.2 11000 300000 35 1 145 3.6 9.5 1 2/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 14.2 11,500 207000 29 0.8 142 4.2 9.5 1 3/5 10/1 28/30 - - NORMALSTUDY - -
- - - 13.2 11,500 300000 29 0.8 145 4.4 9.5 1.1 2/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 13.1 11,500 300000 29 1 142 4.2 9.5 1 3/5 10/1 28/30 - - NORMALSTUDY - -
- - - 13.2 11,500 300000 35 0.8 145 4.2 9.5 1 2/6 12/0.8 25/15 - - NORMALSTUDY - -
- - - 13.9 11,500 300000 29 1 145 4.2 9.5 1 3/5 10/1 25/15 - - NORMALSTUDY - -
- - - 13.2 11,500 300000 29 0.8 142 4.4 9.5 1 3/5 12/0.8 28/30 - + CHOLECYSTITIS - -
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1 45 F 59876 BAIT 12-24 HRS - 30 g + + - 1 40/4.5 4 DAYS - - - 1 11/1.2
2 54 F 39600 BAIT 24-72 HRS - 50 g + + + 4.5 35/3 5 DAYS - - - 1 15/1.5
3 53 F 59894 BAIT 12-24 HRS - 40 g + + - 1 40/4.5 4 DAYS - - - 1.1 13/1
4 54 M 59906 BAIT 12-24 HRS - 30 g + + - 1.1 50/5 4 DAYS - - - 0.9 15/1.3
5 24 M 39640 BAIT 12-24 HRS - 40 g + + - 0.9 35/3 4 DAYS - - - 0.9 16/1.2
6 34 F 39648 BAIT 24-72 HRS - 40 g + + + 5.5 40/4.5 5 DAYS - - - 1.2 12/1.5
7 54 F 59936 BAIT 12-24 HRS - 30 g + + - 0.9 50/5 4 DAYS - - - 0.9 14/1.4
8 24 M 39688 BAIT 3-7 Days - 40 g + + - 1.1 40/4.5 9 DAYS - - - 0.8 13/1.5
9 48 M 39704 BAIT 3-7 Days - 30 g + + - 1.1 50/5 9 DAYS - - - 0.8 14/1
10 34 F 39720 PASTE 6-12 HRS DEATH 60 g + + + 4.5 12/1.2 - - - - - -
11 32 F 59984 BAIT 3-7 Days - 40 g + + - 1.1 40/4.5 9 DAYS - - - 0.8 15/1.5
12 39 M 59996 BAIT 3-7 Days - 30 g + + - 1.1 12/1.2 9 DAYS - - - 0.7 16/0.8
13 48 M 60008 PASTE 6-12 HRS DEATH  80 g + + + 4.9 35/3 - - - - - -
14 54 F 60020 BAIT 3-7 Days DEATH 90 g + + - 1.1 40/4.5 - - - - - -
15 53 M 39792 PASTE 6-12 HRS DEATH 60 g + + + 5.5 50/5 - - - - - -
16 24 M 39808 BAIT 7-14 Days - 40 g + + - 1 40/4.5 15 Days - - - 1 12/1
17 54 F 39824 BAIT 7-14 Days - 30 g + + - 0.9 50/5 15 Days - - - 1.7 13/1.5
18 26 F 60062 BAIT 7-14 Days - 40 g + + - 1.1 40/4.5 15 Days - - - 1.2 13/0.8
19 54 M 60074 BAIT 7-14 Days - 30 g + + - 1.1 35/3 15 Days - - - 0.8 14/0.9
20 31 F 60086 BAIT 7-14 Days - 40 g + + - 1.1 40/4.5 15 Days - - - 0.9 15/1.5
21 48 F 60098 PASTE 6-12 HRS DEATH  80 g + + + 4.5 11/0.9 - - - - - -
22 62 M 39904 BAIT 24-72 HRS - 30 g + + - 0.9 12/0.8 5 DAYS - - - 1 13/1
23 32 F 39920 BAIT 24-72 HRS DEATH 80 g + + - 0.9 50/5 - - - - - -
24 25 M 39936 BAIT 24-72 HRS - 40 g + + - 0.9 40/4.5 5 DAYS - - - 0.9 15/1.2
25 29 F 60146 BAIT 24-72 HRS - 30 g + + - 1 11/0.9 5 DAYS - - - 0.7 16/1.2
26 28 M 39960 PASTE 6-12 HRS DEATH 70 g + + + 6 35/3 - - - - - -
27 24 F 60164 BAIT 24-72 HRS - 40 g + + - 0.9 35/3 5 DAYS - - - 1.1 16/1
28 31 F 39984 BAIT 24-72 HRS - 30 g + + - 0.9 11/0.9 5 DAYS - - - 1.2 16/1.3
29 35 F 60182 PASTE 6-12 HRS DEATH 60 g + + + 4.5 50/5 - - - - - -
30 67 M 60188 BAIT 24-72 HRS - 40 g + + - 0.9 50/5 5 DAYS - - - 1.3 15/1.8
31 50 M 60200 POWDER 24-72 HRS - 30 g + + - 0.9 10/1 5 DAYS - - - 0.8 13/1
32 37 F 40024 POWDER 24-72 HRS - 40 g + + - 1.1 35/3 5 DAYS - - - 0.9 15/1.4
33 67 M 60218 PASTE 24-72 HRS - 30 g + + - 0.9 50/5 5 DAYS - - - 0.7 15/1.3
34 62 F 60230 PASTE 6-12 HRS DEATH 70 g + + + 6 10/1 - - - - - -
35 24 F 40064 PASTE 24-72 HRS - 40 g + + - 1 35/3 5 DAYS - - - 0.6 17/1.3
36 31 M 40080 PASTE 24-72 HRS - 30 g + + - 1 35/3 5 DAYS - - - 1.1 12/1.3
37 29 M 40088 PASTE 24-72 HRS - 40 g + + - 1 50/5 5 DAYS - - - 1.1 11/1
38 24 F 60254 PASTE 24-72 HRS - 30 g + + - 1.1 12/0.8 5 DAYS - - - 1.2 14/1.6
39 31 F 40120 PASTE 6-12 HRS DEATH 60 g + + + 4.5 35/3 - - - - - -
40 24 F 60296 PASTE 24-72 HRS - 40 g + + - 1 10/1 5 DAYS - - - 1 15/1.4
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1 20 F 59870 PASTE 6- 12 HRS 15 g - 120 3.4 5 DAYS - 134 3.6
26 22 F 39680 PASTE 12-24 HRS 15 g - 110 3.7 5 DAYS - 135 3.7
41 48 F 59990 POWDER 24-72 HRS 15 g + 136 2 5 DAYS - 136 3.9
72 28 M 39864 PASTE 24-72 HRS 15 g - 120 3.9 5 DAYS - 140 4.2
78 29 F 39888 POWDER 24-72 HRS 15 g + 142 2.3 5 DAYS - 139 3.8
85 67 M 60122 PASTE 24-72 HRS 5 g - 115 3.8 5 DAYS - 142 3.3
100 37 F 39976 POWDER 24-72 HRS 5 g - 100 4 5 DAYS - 145 3.9
103 62 M 60176 POWDER 24-72 HRS 5 g + 140 2.2 5 DAYS - 143 4.2
114 29 M 40032 POWDER 24-72 HRS 5 g + 138 2.7 5 DAYS - 142 4.3
131 32 F 60260 POWDER 24-72 HRS 5 g + 140 2.1 5 DAYS - 140 3.6
  
  
 
 
 
 
 
 
 
 
